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ABSTRACT
 Medical marijuana is legal in twenty-nine of the United States and an additional 
nineteen states have passed legislation for cannabidiol (CBD) treatment of drug-resistant 
epilepsy, such as Dravet Syndrome (DS) which is diagnosed in children as young as two 
months. While CBD has shown anecdotal and recently clinical trial efficacy in reducing 
seizure frequency in DS patients, little is known about the potential adverse side-effects 
on child physiology, brain development, adult disease, or subsequent generations. 
Moreover, CBD is rarely administered without including low concentrations of Δ9-
tetrahydrocannabinol (THC). The goal of this project is to characterize the relative 
morphological, behavioral, reproductive, and multigenerational toxicities following a 
developmental F0 exposure to 0.024 - 5 mg/L (0.08 - 16 μM) THC or 0.006 - 1.2 mg/L 
(0.02 - 4 μM) CBD. In this study, THC was used as a positive control due to its established 
developmental toxicities. An additional goal of this project was to analytically confirm THC 
and CBD concentrations during waterborne exposure as well as the bioconcentration in 
zebrafish. Following a developmental exposure, CBD posed similar risk to development, 
reproduction, and behavior as THC, but at much lower concentrations. Also, CBD 
bioconcentrated in zebrafish more readily than THC. To our knowledge, this is the first 
study to systematically compare the harmful effects on development and behavior of the 
two most prevalent and widely used phytocannabinoids. While most patients with drug-
resistant forms of epilepsy and debilitating seizures choose cannabinoids in desperation, 
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more research is necessary into their developmental toxicity to better understand both 
their therapeutic and toxic mechanisms of action.      
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CHAPTER 1 INTRODUCTION 
1.1 Project Overview 
 Epilepsy afflicts an estimated 65 million people worldwide (Thurman et al., 2011) 
and roughly 30% of patients have drug-resistant epilepsy (Romanelli et al., 2012; Williams 
et al., 2014) wherein seizures are not adequately controlled with existing antiepileptic 
drugs. Dravet syndrome (DS) is a prominent drug-resistant epilepsy beginning in infancy 
with an incidence of roughly 1:16,000 to 1:21,000 (Krueger and Berg 2016). Among those 
diagnosed with DS, ~75% carry a mutation in the voltage-gated sodium channel Nav1.1 
(SCN1A) (Krueger and Berg, 2016). Efforts in validating a DS mouse model have proven 
difficult due to unforeseen epileptic phenotypes (Grone and Baraban, 2015). Therefore, 
zebrafish have become an excellent alternative for DS modeling as a result of inexpensive 
breeding, easy introduction of genetic alterations, and proven developmental modeling 
capabilities (Hortopan et al., 2010). Initial research utilizing scn1a deficient zebrafish has 
identified new drug leads with potentially higher efficacies for DS (Baraban et al., 2014; 
Zhang et al., 2015). Additionally, efforts in more generalized epileptic modeling using 
zebrafish are also promising (Afrikanova et al., 2013; Buenafe et al., 2013; Rahn et al., 
2015; Rosa-Falero et al., 2015). 
Due to relaxed prohibitions on marijuana use and therapeutic potential of cannabis 
constituents in adolescent drug-resistant epilepsy, exposure of children to THC and CBD 
is increasing. Yet the consequence of developmental exposure to cannabinoids on the 
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potential etiology of subsequent adult or multigenerational toxicity is currently unknown. 
The goal of this project was to use the highly relevant zebrafish (Danio rerio) model to 
study the potential toxicity of THC and CBD. Specifically, an adverse outcome pathway 
(AOP) paradigm was used to eventually establish mechanistic relationships between 
altered gene expression and phenotypic defects including developmental deformities, 
behavioral alterations, and decreased reproductive success. THC was expected to have 
adverse side-effects on brain development and reproduction, but little was initially known 
about the toxicity of CBD. CBD is important due to  popular CBD medications such as 
CBD oil administration (e.g. Charlotte’s WebTM, http://www.theroc.us/) to patients, 
especially young children, with epilepsy (Lindsey, 2016). While CBD has effective 
antiepileptic properties (Devinsky et al., 2017), little is known about the potential for 
persistent adverse outcomes. Mechanistic understanding underlying toxicity and 
therapeutic efficacy of CBD is urgently needed (Porter and Jacobson, 2013; Szaflarski 
and Martina Bebin, 2014). 
 When conducting literature searches related to CBD toxicity or mechanisms of 
therapeutic action (Izzo et al., 2009; Pertwee, 2008) there are shockingly few published 
studies. This is particularly perplexing given that CBD is being prescribed to a pediatric, 
albeit desperate for treatment, population. There is a critical need for better understanding 
of the molecular and physiological consequences of developmental exposure to THC and 
CBD. AOPs, similar in concept to “mode of action”, provide a conceptual paradigm to link 
a direct molecular initiating event between a xenobiotic and biomolecule and track effects 
up biological levels of organization to the key risk assessment endpoint namely population 
response (Ankley et al., 2010). AOPs significantly advance traditional toxicity testing 
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paradigms and make use of new technological advances in transcriptomics, proteomics, 
metabolomics, high-throughput assays, and bioinformatics (Villeneuve et al. 2014). Our 
focus on brain neurodevelopment and behavior is particularly timely and will directly 
complement new brain neuronal activity maps and behavior assays currently being 
developed (Ahrens et al., 2013; Stewart et al., 2014). 
 Both the developmental origins of health and disease (DOHaD) and the potential 
for subsequent multi- and/or transgenerational adverse outcomes are becoming more 
appreciated in the scientific and health care communities (Heindel and Vandenberg, 
2015; McMullen and Mostyn, 2009). Recently our lab (Corrales et al., 2014; Corrales et 
al., 2014)  and others (Baker et al., 2014) have proven that zebrafish are an advantageous 
model for studying mechanisms of multi- and transgenerational toxicity. Capitalizing on 
advantages of high fecundity, low culture costs, transparency and conserved (Howe et 
al., 2013) developmental biology and genomics (Kettleborough et al., 2013), zebrafish is 
an innovative approach for studying multigenerational toxicity. No existing mammalian 
model affords all of these advantages. An additional distinctive advantage of using 
zebrafish is the >1000 available transgenic lines that facilitate deformity scoring and 
phenotypic anchoring (Weinstein, 2004). Namely, we will use transgenic fli [Tg(fli1:egfp)] 
fish. Fli is a transgenic line wherein after 14 hours post-fertilization (hpf) the zebrafish 
stably express enhanced green fluorescent protein in vascular endothelial cells (Lawson, 
2002). Similar fish models have proven useful in high-throughput developmental 
toxicology screening (Panzica-Kelly et al., 2010) of, for example, the ToxCast database 
(Raftery et al., 2014). Importantly, developmental landmarks in zebrafish as they relate to 
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AOP development have also been recently established (see Figure 1.1 in (Villeneuve et 
al., 2014)). 
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Figure 1.1 Adverse Outcome Pathway for THC and CBD Mediated Effects. 
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 CBD efficacy in epileptic animal models and children with drug-resistant epilepsy 
is intriguing and will continue to gain attention as individual states in the United States 
legalize the use of medical marijuana (Murphy and Ooyen, 2016). Unfortunately, while 
CBD shows efficacy in reducing seizure frequency, little is known about the potential 
adverse side-effects of CBD on child physiology, brain development, adulthood, or 
offspring. Furthermore, the Schedule I designation of CBD limits its availability for 
research and as a therapeutic (only approved for use in patients in 29 states) so new 
plant-derived molecules or synthetic compounds may have enhanced efficacy against 
epilepsy without scheduling liabilities. Our study design, using zebrafish, allows us to 
determine the relative dose-dependent effects of THC and CBD in an easily screened 
developing animal model. Our study provides significant new information relevant for 
physicians and policy makers; specifically THC and CBD were assessed for causing: 
 developmental stage-specific differential gene expression in F0 and F1 larvae  
 adverse developmental morphologies (e.g. growth, edemas, brain development, 
etc.) 
 reproductive success, and 
 behavioral phenotypes in exposed F0 larvae and unexposed F1 larvae.  
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Figure 1.2 Adverse Outcome Pathway Schematic. Our approach began with a 96 hour 
post fertilization (hpf) exposure to various concentrations of cannabinoids and structural 
analogues. F0 larvae were analyzed for morphological, molecular, and behavioral 
deformities. Exposed F0 fish were raised to maturity and undergo molecular, behavior, 
and reproduction assessments. Finally, we spawned exposed F0 adults and conducted 
similar analysis on F1 larvae. 
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1.2 History of Cannabis sativa 
 Marijuana (Cannabis sativa; Cannabis) has been used for several millennia for 
medicinal purposes. The first recorded evidence of medical cannabis dates back nearly 
five millennia to the Chinese emperor, Shen-Nung (Bostwick, 2012), and eventually 
spread westward to India and Africa around 2000 BC. In North America, hemp, an 
industrialized form of Cannabis sativa containing very low concentrations of THC, is 
thought to have first arrived with Puritan colonizers in the early seventeenth century. 
Toward the middle of the seventeenth century, hemp was being produced in large 
quantities and used for its fibrous characteristics such as paper, cloth, and cordage for 
marine vessels (Will, 2004). Throughout the eighteenth and nineteenth century, hemp 
demand and production began to decrease as alternative forms of water transportation 
were developed, such as steam boats (Will, 2004). Politics also played a role in hemp’s 
demise via the 1937 Marijuana Tax Act which did not completely outlaw hemp production, 
but placed a tax and authorization that the crop would no longer be used for illicit 
purposes.  
 Medicinal cannabis was first introduced to the United States in 1830 by W.B. 
O’Shaughnessy, a Scotland born pharmacist (Bostwick, 2012). O’Shaughnessy claimed 
cannabis could be used therapeutically for indications such as nausea, pain, and even 
seizures or convulsions. In the late 1800s through the early-1900s, cannabis was widely 
used across the United States and found in numerous pharmaceuticals, that is, until the 
1937 Marijuana Tax Act was enacted (McKenna, 2014). Much like the hemp industry, 
medicinal use of cannabis was also limited and ultimately discontinued after the war on 
drugs campaign by the Nixon administration, which lead to the Controlled Substances Act 
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of 1970, part of the Comprehensive Drug Abuse Prevention and Control Act of 1970. The 
Controlled Substances Act contained five classifications of potential of abuse. Cannabis 
was classified a Schedule I drug, which is the most restrictive classification and proposes 
no medical benefit.  
 Within the late 1990’s and early 21st century, medical cannabis has shown a strong 
resurgence for therapeutic uses ranging from depression, schizophrenia, and chronic 
pain to epilepsy and even cancer, due to complications with chemotherapy. Even though 
medical cannabis has shown potential in many areas of therapeutic treatment, it is still 
characterized as a Schedule I drug in the United States via the 1970 Controlled 
Substance Act and is illegal under Federal Law. However, 29 states have passed medical 
cannabis legislation within the United Sates and a number of additional states possess 
laws specific for CBD drug trials and regulate the way in which patients obtain medical 
cannabis (ProCon.org, 2017). Cannabis usage per state varies drastically, some states’ 
(RI, VT, AK, OR, WA, CO, MT) are estimated to have >10% cannabis use within the past 
month (Palamar et al., 2014). Exposure to cannabinoids will likely increase due to an 
increasing number of states relaxing cannabis regulatory policies and allowing medical 
cannabis prescriptions (Consroe et al., 1982).  
 In 1999, the Institute of Medicine released a study suggesting cannabis may have 
some medicinal benefit for applications such as loss of appetite, nausea and vomiting, 
and severe pain (Bostwick, 2012). More recently, CBD has gained traction in the 
treatment of pediatric drug-resistant epilepsy. In a study with 19 children with a range of 
epileptic disorders (Dravet syndrome, Doose syndrome, Lennox-Gastaut syndrome, and 
idiopathic epilepsy) treated with CBD-enriched cannabis (from 0.5-28.6 mg/kg/day CBD 
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and 0-0.8 mg/kg/day THC), 84% (n = 16) of the children experienced reduced seizure 
events and 11% had no seizure events (Porter and Jacobson, 2013). CBD showed an 
improved therapeutic outcome in a wide variety of epilepsy animal models including trans-
corneal electroshock and PTZ-induced seizure models (Jones et al., 2010; Renard et al., 
2014). While CBD may be an effective treatment option for children with epilepsy, the 
effects of CBD on child development and behavior and/or effects of childhood CBD 
treatment in adulthood and on future offspring are currently unknown (Szaflarski and 
Martina Bebin, 2014). In contrast, studies have shown a direct connection between 
chronic cannabinoid receptor agonist exposure and lifelong cognitive dysfunction in 
adolescence (Renard et al., 2014). Data suggests a reduction in memory, attention, 
decision-making, IQ, and cognitive inhibition (Higuera-Matas et al., 2015; Jutras-Aswad 
et al., 2009). Additionally, the effects of chronic cannabis abuse on the developing brain 
and early cognition include the induction of tremors, increased startle response, and poor 
habituation to stimuli in newborns and infants (Huizink and Mulder, 2006; Panula et al., 
2010). 
 In the end, despite these suggested therapeutic effects of CBD for seizure control 
and the adverse neurobehavioral outcomes of THC exposure, the molecular 
underpinnings of these effects are not fully known. Because of the relatively conserved 
neuroanatomy, neurochemistry (Lam et al., 2006) including cannabinoid receptor 1 
signaling (Migliarini and Carnevali, 2009; Rodriguez-Martin et al., 2007) and behavior 
(Akhtar et al., 2013; Bruni et al., 2014) between zebrafish and mammals, the AOP linking 
molecular to organismal responses is highly translatable to humans. Symptoms of THC 
developmental toxicity include pericardial and yolk sac edemas, curved body axis and 
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behavioral habituation at 120 hpf (Noyes et al., 2015) while acute adult exposure caused 
hypolocomoter/anxiogenic-like responses (Grossman et al., 2010). Additionally, larval 
zebrafish respond to convulsant drugs (e.g. pentylenetetrazol (PTZ) recapitulating 
seizures similar to mammals.  
 
1.3 Cannabinoid Signal Transduction 
 More recently, the scientific community has focused its efforts into the effects of 
the endocannabinoid system (EDC) on neuronal activity, inflammation, energy 
metabolism, regulation of the immune system, reward systems, and memory. The EDC 
has been implicated in diseases such as, type II diabetes and liver disease. The primary 
receptors involved in cannabinoid signal transduction are cannabinoid receptor I (CB1) 
and II (CB2) that operate in a G-protein-coupled receptor (GPCR) manner. Distribution of 
cannabinoid receptors differ receptor to receptor; CB1 is currently thought to primarily 
concentrate in the central and peripheral nervous systems while CB2 is primarily 
expressed in the immune system. Although, much debate encompasses the individual 
actions of CB1 and CB2, CB1 receptors have been connected to cardiovascular activity, 
regulation of the gastrointestinal tract, stress, and olfaction. CB2 actions are less known, 
but include immune regulation and neurodegeneration (Szaflarski and Martina Bebin, 
2014).  
 The EDC is  highly conserved in vertebrates encompassing a wide variety of signal 
processes from neuronal development and signaling to immune response 
(Basavarajappa et al., 2009; B Migliarini and Carnevali, 2009; Psychoyos et al., 2012; 
Watson et al., 2008). These processes are carried out via two GPCRs, CB1 receptor 
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(CNR1, human gene, CB1, human protein; Cnr1, rodent gene, CNR1, rodent protein; 
cnr1, zebrafish gene, Cnr1, zebrafish protein) and CB2 receptor (CNR2, human gene, 
CB2, human protein; Cnr2, rodent gene, CNR2, rodent protein; cnr2, zebrafish gene, 
Cnr2, zebrafish protein) (Krug and Clark, 2015). 
 Due to recent advancements in EDC mapping and cannabinoid receptor tissue 
localization, focus on cannabis efficacy in various other disorders, such as epilepsy, has 
increased. Regarding cannabis therapeutic usage, two endocannabinoid extracts are of 
current interest; the primary psychoactive compound THC and a non-psychoactive 
compound, CBD. While the mechanisms of action are not entirely known, THC and CBD, 
in concert with the EDC, have an important mechanistic role in the propagation and 
maintenance of seizures in animal models.  
 THC has high affinity for the CB1 receptor, while CBD is thought to have a very 
low CB1 affinity, but has shown the ability to displace CB1 antagonists (Szaflarski & 
Martina Bebin., 2014; Wallace et al., 2002; Wallace et al., 2003 & Jones et al., 2010). 
Although cannabinoid efficacy has been shown in maximal electroshock animal models 
versus controls, a wide range of blind studies in human epileptic patients have proven 
inconclusive in THC and CBD treatment (Szaflarski & Martina Bebin, 2014). In addition 
to CBD having an increased efficacy in maximal electroshock animal models, CBD has 
shown an improved therapeutic outcome in a wide variety of epilepsy animal models; 
including transcorneal electroshock models and pentylenetretrazole (Consroe, et al., 
1982 & Jones et al., 2010). In epileptic animal models, CBD is more effective active 
cannabinoid compound. In the United Kingdom, THC and CBD are being used in Sativex, 
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a THC:CBD (1:1) pharmaceutical used to treat severe pain caused by multiple sclerosis 
and cancer (Jones et al., 2010).  
 Activation of GPCRs occurs when an endogenous or exogenous ligand interacts 
with the binding pocket resulting in a guanine exchange between guanosine diphosphate 
(GDP)/guanosine triphosphate (GTP) and interplay with α-, β-, and γ-subunits 
(Basavarajappa et al., 2009). Guanine exchange factors (GEF) catalyze the transfer of 
guanine to guanosine triphosphate which is coupled with the α-subunit. Once GDP is 
replaced with GTP, the α-subunit detaches from the βγ-subunits and diffuses across the 
membrane activating an effector turning on the GPCR (Basavarajappa et al., 2009; 
Norman and Litwack, 1997). Signaling can be further turned “off” by hydrolysis of GTP 
via GTPase resulting in the re-association of GDP and α-subunit to the βγ-subunit 
complex (Wettschureck and Offermanns, 2005). Cannabinoid receptors belong to the 
Gi/Go family of GCPRs which refers to specific type of α-subunit. Gi/Go subfamily of 
GCPRs have an inhibitory effect on adenylyl cyclase decreasing cyclic adenosine 
monophosphate (cAMP) while also positively affecting potassium channels activity 
(Birnbaumer, 2007). 
 Endogenous ligands for cannabinoid receptors (endocannabinoids) have been 
well established within the past few decades and possess a broad range of action in a 
large variety of pathways. Notably, anandamide (AEA), was the first endocannabinoid 
discovered in 1992 by (Devane et al., 1992) from porcine brain fractions. AEA is regarded 
as a partial agonist of CB1 receptor and an inactive CB2 agonist (Szabo and Hoffman, 
2012). A second endocannabinoid, 2-arachidonylglycerol (2-AG), was elucidated from 
canine gut (Mechoulam et al., 1995; Sugiura et al., 1995). 2-AG is considered a full 
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agonist at both CB1 and CB2 (Szabo and Hoffman, 2012). A few other endocannabinoids 
have been identified, 2-AG ether, virodhamine, and N-arachidonyl-dopamine, however 
little is known with regard to their physiological roles (Basavarajappa et al., 2009). 
Chemical structures of the listed endocannabinoids and phytocannabinoids are 
represented in Figure 1.3-1.4.   
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Figure 1.3 Endogenous cannabinoid receptor ligand structures. (PubChem, 2017).  
 
Figure 1.4 Most prevalent phytocannabinoid structures. (PubChem, 2017).  
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 CB1 belongs to the rhodopsin subfamily A13 of GPCRs and is primarily expressed 
in regions of the brain imperative for memory, cognitive development, and learning 
(Demuth and Molleman, 2006). The physiological role of CB1 was first characterized by 
(Howlett and Fleming, 1985) using the phytocannabinoid, THC. Following THC exposure 
to neuroblastoma cells, adenylyl cyclase was inhibited which eventually lead to a 
reduction of cAMP. Further analysis using a CB1 antagonist, AM 281, showed a reversal 
of this inhibitory effect leading to recovered cAMP production. cAMP is an imperative 
second messenger in cells with three distinct targets for signal transduction: cAMP protein 
kinase (PKA), cAMP response element binding protein (CREB), and cAMP guanine 
exchange factors (EPACs) (Goodman and Gilman, 2011). PKA is conformationally 
activated by increased intracellular concentrations of cAMP leading to phosphorylation of 
threonine and serine residues on target proteins which further enhance downstream 
signaling. The target proteins of PKA can range from metabolic enzymes to highly 
regulated proteins involved in kinase activity. CREB activation can lead to important gene 
expression-related processes such as, increased transcription of the aryl hydrocarbon 
receptor (AhR), glucocorticoid receptor, insulin, and many others. EPACs are involved in 
many cell functions including activation of the Ras family of GTPases and can act 
independent or in concert with PKA (Goodman and Gilman, 2011).     
 In order to better elucidate the type of GCPR for which cannabinoid receptors 
represent, pertussis toxin (PTX), a Gi/o specific uncoupler of the α-subunit (Mangmool and 
Kurose, 2011), was used to block the inhibitory action of THC. This competitive inhibition 
confirmed that CB1 is a Gi/o specific GCPR (Howlett and Fleming, 1985). The complexity 
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of cannabinoid signaling can be further evaluated through the nine isozymes of adenylyl 
cyclase categorized in six classes (Demuth and Molleman, 2006):  
 Class I: AC-1. Found in the brain and inhibited by Gβγ/Giα and activated by 
Ca2+/calmodulin. 
 Class II: AC-II, AC-IV, and AC-VII. Found in the brain and additional unknown 
locations. With Gαs, these isoforms are turned on by Gβγ. 
 Class III: AC-III. With Gαs, AC-III is activated by Ca2+/calmodulin. 
 Class IV: AC-V and AC-VI. Found in heart and brain, Giα inhibition with Ca2+. 
 Class V: AC-VIII. Found in brain with Ca2+/calmodulin activation. 
 Class VI: AC-IX. Found in brain and skeletal muscle and regulated by Gαs.  
 Tissue specificity along with complex regulatory mechanisms of adenylyl cyclase 
increases the likelihood of phytocannabinoid toxicities responding in contrasting ways 
depending on the cannabinoid receptor concentration in target and adjacent tissues. 
Along with adenylyl cyclase activation via CB1 receptors, mitogen-activated protein 
(MAP) kinases have also been correlated with cannabinoid signaling. Synthetic 
cannabinoid CP 55,940 as well as HU-210, a synthetic cannabinoid found in the popular 
recreational drug Spice, activate MAP kinase activity in Chinese hamster ovary (CHO) 
cells; however, off-target effects of these cannabinoids are still under investigation 
(Bouaboula et al., 1995; Galve-Roperh et al., 2002). Additionally, this action was reversed 
following PTX exposure which implies Gi/o (i.e., CB1/CB2) involvement. In vivo studies in 
rodents after THC exposure have also supported MAP kinase activation claims via CB1 
(Valjent et al., 2001). MAP kinase is a very important CB1 signaling target especially in 
this present study due to the ramifications of c-fos and brain derived neurotrophic factor 
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(BDNF) (Demuth and Molleman, 2006). Following THC exposure in mice, (Derkinderen 
et al., 2003) both c-fos and BDNF had increased protein concentration and were 
subsequently reduced after MAP kinase inhibition.  
 Possibly the most elusive signaling pathways of CB1 and possibly cannabinoids 
independent of receptors is the regulation of ion channels. Ion channel regulation through 
CB1 or cannabinoids directly is thought to be the primary mechanism by which 
neurotransmitter release an affect following exposure. Cannabinoids (CP 55,940, AEA, 
and WIN 55,212-2) were first described (Felder et al., 1993; Mackie and Hille, 1992) to 
negatively modulate N-type voltage-operated calcium channels (VOCCs) reducing Ca2+ 
influx through CB1 mediated processes. Gi/o type GPCRs were confirmed to mediate this 
interaction through PTX reversal (Mackie et al., 1993). Cannabinoids also act 
independently in inhibiting Ca2+. SR 141716A, a potent antagonist of cannabinoid 
receptors in the brain is not effective in blocking the inhibitory role of WIN 55,212-3 on 
Ca2+ signaling (Shen and Thayer, 1998). One interesting component of ion channel 
regulation via cannabinoids is that this signaling is CB1-specific with CB2 lacking this 
characteristic.  
 CB2 also acts in an adenylyl cyclase and MAP kinase dependent manner via Gi/o. 
As mention previously, CB2 receptors are currently thought to not possess ion channel 
activation (Felder et al., 1995). Also, verified through the lack cAMP accumulation in CHO 
cells following HU210 treatment, Gs coupling is not a characteristic of CB2 receptors 
(Glass and Felder, 1997). In order to further elucidate CB2’s cannabinoid activity, MAP 
kinase (p42/p44) activation in CHO cells expressing high concentrations of CB2 can be 
reversed using PTX (Bouaboula et al., 1996). CB2 has also been implicated in the signal 
 19 
 
transduction of THC which activates PI3K/PKB and Raf-1 translocation in prostate cells, 
PC-3. Treatment of PC-3 with CB2 receptor antagonist, SR 144528, blocks this action 
(Sánchez et al., 2003). Additionally, the immune system characteristics of CB2 have been 
implied in studies showing IL-2 inhibition, presumably downstream of MAP kinase 
inhibition, in mouse spleen tissue following WIN 55,212-2 exposure (Kaplan and 
Kaminski, 2003). However, it should be noted that WIN 55,212-2 has low affinity (3.3 ± 
0.4 nM) to CB2 compared to other agonist such as AEA (1940 ± 240 nM), and WIN 
55,212-2 has substantially greater affinity for CB1 (62.3 ± 31 nM) (Felder et al., 1995).  
 
1.3.2 Zebrafish Endocannabinoid System 
 One of the benefits of using zebrafish as a cannabinoid toxicity model is the 
conserved nature of their EDC to mammals. The EDC system is not well conserved in 
invertebrate model organisms such as, Drosophila or C. elegans (Krug and Clark, 2015). 
Zebrafish express both cannabinoid receptors primarily in the brain (hind-, mid-, and 
forebrain), but also in peripheral tissues such as ovary, intestine, spleen, and heart (Lam 
et al., 2006; Migliarini and Carnevali, 2009; Rodriguez-Martin et al., 2007). CB1 mRNA 
(cnr1) has been observed as early as the three somite stage and increases through the 
25 somite stage, while CB1 protein (63 kDa) has been measured via whole-mount in situ 
hybridization at 48 hpf through 15 days post fertilization (Migliarini and Carnevali, 2009). 
CB2 mRNA has been less studied; however, Rodriguez-Martin et al (2007) observed CB2 
expression in brain regions in adult zebrafish with RT-qPCR only. In situ techniques to 
identify CB2 in the brain were inconclusive (Rodriguez-Martin et al., 2007).  
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 Regarding endocannabinoid signaling, diacylglycerol lipase (DAGL) and fatty acid 
amide hydrolase (FAAH) have been studied minimally in zebrafish. DAGL, the primary 
catalytic enzyme for the synthesis of 2-AG, expression has been observed in the 
hypothalamus, telencephalon, and hindbrain regions of developing zebrafish at 
comparable concentrations to cnr1 (Watson et al., 2008). One difference between DAGL 
and cnr1 expression is the presence of DAGL in the posterior and anterior hindbrain 
(Watson et al., 2008). Zebrafish retina is associated with FAAH expression; however, 
studies are lacking in this area of zebrafish biology (Yazulla and Studholme, 2001).   
 
1.4 Cannabinoid Toxicity 
 Toxicities resulting from THC exposure are well documented and range from 
cognitive decline to reproductive impairments; however, adverse effects following CBD 
exposure have been less explored. Elucidating cannabinoid pharmaceutical prowess has 
been researched since the early 1940’s. In humans, THC is an established reproductive 
toxicant (Lewis et al., 2012). Cannabis use in men causes a reduction in 
endocannabinoids (e.g. AEA and 2-arachidonoylglyceral) responsible for THC signal 
transduction in seminal plasma. Moreover, infertility is a direct consequence of THC 
exposure via the transient receptor potential cation channels (TRPV1) receptor (Lewis et 
al., 2012). Studies also suggest low birth weights (< 2,500 g) and preterm deliveries in 
children after regular maternal cannabis use (Gunn et al., 2016). One of the major issues 
related to the previously mentioned research is how cannabis is consumed. Most current 
literature studying exposure effects involve smoking cannabis; therefore, it is impossible 
to control for the coupled onslaught of products from combustion such as polycyclic 
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aromatic hydrocarbons (PAHs). Therefore, the studies discussed herein will be limited to 
those conducted in controlled settings following pure compound exposure in a host of 
relevant model organisms. In addition, THC is the most abundant compound found in 
cannabis, hence data derived directly from solely CBD exposure is lacking in the 
toxicology community. Select phytocannabinoid toxicity publications are listed in Table 
1.1.   
 
1.4.1 Reproduction and Teratogenicity 
 One of the earliest publications studying the potential teratogenicity of 
cannabinoids was in 1967 by Persaud and Ellington. Mouse embryos were I.P. exposed 
to 16 mg/kg cannabis resin at 1 to 6 days of gestation and screened for developmental 
abnormalities and pregnancy success (Persaud and Ellington, 1967). Embryos exposed 
at gestational day 6 experienced impeded growth, while embryos exposed from day 1 
through 6 of gestation were more likely to undergo fetal resorption. However, no 
detectable developmental malformations were observed in exposed embryos (Persaud 
and Ellington, 1967). The same group later studied the potential teratogenic effects of 4.2 
mg/kg cannabis resin on pregnant rats again on 1 to 6 days of gestation. Fetal resorption 
as well as malformed fetuses were significantly increased in exposed mothers compared 
to control (Persaud and Ellington, 1968). It should be noted that the previous studies were 
both conducted with crude cannabis resin which includes a number of phytocannabinoids 
including undisclosed compounds. Early studies have also been conducted in rabbits for 
potential teratogenicity following cannabis exposure. Resorption percentages in addition 
to runt-like phenotypes were greatly increased after mothers were exposed to amounts 
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of cannabis extract > 250 mg/kg (Geber and Schramm, 1969). Developmental 
malformations were also observed in embryos whose moms were exposed to 
concentrations > 250 mg/kg (Geber and Schramm, 1969). More recent literature has also 
focused on the potential developmental and embryonic effects of THC, synthetic THC 
(sTHC), and endogenous CB ligands. Win 55212-2, THC, CP 55,940, and AEA can inhibit 
mouse blastocyst formation, significantly arresting development between the four to eight 
cell stage (Paria et al., 1995). Interestingly, the same study showed CBD and 2-AG to be 
ineffective against developmental inhibition (Paria et al., 1995).  
 The effects of endogenous cannabinoids adversely affecting development and 
fertility is well known (Lockwood, 2000; Maccarrone and Finazzi-Agro, 2004). For 
example, AEA, through MAPK mediated pathways reduce blastocyst viability; therefore, 
implying that AEA degradation is crucial for implantation and early development (Wang 
et al., 2003). Consequently, FAAH, the enzyme responsible for AEA’s degradation, is also 
correlated with the early loss of pregnancy (Lockwood, 2000). Specifically, FAAH is 
needed in order to maintain pregnancy, so patients lacking FAAH are more likely to 
miscarry than patients expressing FAAH at concentrations above a threshold 
(Maccarrone and Finazzi-Agro, 2004). Fluctuating FAAH and AEA levels during early 
stages of pregnancy through fetal development have been observed in both humans and 
mice (Paria and Dey, 2000). 
 Following the initial teratogenic screens in mammals, some follow-up studies were 
conducted in zebrafish measuring embryo toxicity and development. Zebrafish embryos 
were exposed to sTHC at concentrations ranging from 1 to 10 mg/L and subsequently 
screened for developmental abnormalities and involuntary tail movement. Embryos 
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exposed to concentrations > 5 mg/L sTHC experienced fewer spontaneous tail twitches 
compared to control, suggesting potential toxicity relating to the CNS (Thomas, 1975). 
Thomas also observed a significant increase in mortality at 5 and 10 mg/ml sTHC. 
(Thomas, 1975). While Thomas was not the first to elucidate zebrafish developmental 
toxicities (Battle and Hisaoka, 1952; Hisaoka, 1958), his work with zebrafish and THC 
helps us understand historical data and how gaps still exist in cannabis’ toxicity profile.  
 The developmental and teratogenic properties of phytocannabinoids have also 
been characterized in zebrafish (Akhtar et al., 2013; Stewart and Kalueff, 2014; Thomas, 
1975; Wright et al., 1976). Initial studies have focused primarily on embryo survival, while 
more recent research has eluded to behavioral phenotypes and neurotoxicity (Akhtar et 
al., 2013; Nazario et al., 2015a; Stewart and Kalueff, 2014). In zebrafish, THC LC50 
concentrations were first established by (Akhtar et al., 2013) at roughly 3.37 mg/L, which 
is consistent with our findings. Akhtar’s group also observed curved axis, yolk sac and 
pericardial edemas (> 0.6 mg/L) as well additional dysmorphologies that were not 
reported such as craniofacial deformities following THC exposure. Our findings confirm 
the dysmorphologies seen by Akhtar. 
 
1.4.2 Cognitive Impairment and Behavior 
 Cannabinoids have the ability to not only affect neurodevelopment at the molecular 
and structural level, but chronic use can also drastically impair learning, memory, and 
cognitive ability (Akhtar et al., 2013; Fishbein et al., 2012; Hampson et al., 1989; Horrall 
et al., 1976; Long et al., 2010; Morgan et al., 1988; Nazario et al., 2015a; Renard et al., 
2014; Ruhl et al., 2014; Stewart and Kalueff, 2014). Consideration of exposure windows 
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is imperative for the variety of adverse outcomes. For example, chronic use in adolescent 
aged children is correlated with impulsive behavior, impaired executive function and 
decision making, a reduction in comprehensive IQ, and can negatively affect attention 
and memory (Becker et al., 2010a, 2010b; Crane et al., 2013; Dougherty et al., 2014; 
Ehrenreich et al., 1999; Fontes et al., 2011; Medina et al., 2010; Meier et al., 2012; 
Schweinsburg et al., 2008; Solowij et al., 2012).  
 Memory is a basic measurement of neurocognitive function and predictor of 
fundamental mental fitness. Females seem to be more susceptible to the adverse effects 
of chronic cannabis use, especially as it relates to memory tasks (Crane et al., 2013). It 
has even been postulated that cannabis may interrupt hippocampal dendrite maturation 
in an estrogen-dependent manner (Gillies and McArthur, 2010). However, both males and 
females perform poorly in memory recall assessments and decision making following 
chronic cannabis use (Crane et al., 2013). 
 Behavioral observations were conducted in zebrafish following THC exposure 
during early stages of development (Akhtar et al., 2013) and later in adulthood 
(Champagne et al., 2010; Nazario et al., 2015a; Ruhl et al., 2014; Stewart and Kalueff, 
2014). One of the primary mechanisms for characterizing neurodevelopmental toxicities 
in zebrafish is via a light:dark cycling assessment (Kirla et al., 2016). Both acute (1, 4, 12 
hour) and chronic (96 hour) exposure reveal THC and sTHC (WIN 55,212-2 and CP 
55,940) significantly reduced locomotor behavior in zebrafish (Akhtar et al., 2013). In adult 
zebrafish, researchers have conducted more stringent behavioral tests including, learning 
(Braida et al., 2014; Ruhl et al., 2014; Saili et al., 2012), anxiety and stress (Jesuthasan, 
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2012; Nazario et al., 2015a, 2015b; Saili et al., 2012; Stewart and Kalueff, 2014), and 
social attributes (Grossman et al., 2010; Kalueff et al., 2014). 
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Table 1.1 Select Phytocannabinoid Toxicity Publications 
 
 
Species Phytocannabinoid Experimental Endpoints References 
Zebrafish THC 
Lethality; Development; 
Behavior; Reproduction 
(Akhtar et al., 2013; 
Thomas, 1975; Wright et 
al., 1976) 
  Cognitive Function (Ruhl et al., 2014) 
 CBD Metabolism (Silvestri et al., 2015) 
Rat THC Lethality; Physiology (Phillips et al., 1971) 
  Metabolism (Narimatsu et al., 1990) 
  Reproduction (Wright et al., 1976) 
 CBD Food Intake (Koch, 2001) 
Mouse THC Reproduction; Development (Harbison et al., 1977) 
  Lethality; Physiology (Phillips et al., 1971) 
 CBD Metabolism (Pelkonen et al., 2008) 
  Physiology (Dirikoc et al., 2007) 
Pig THC Metabolism (Brunet et al., 2006) 
Monkey THC Physiology; Metabolism (Slikker Jr et al., 1991) 
 CBD Convulsions; Organ Weight (Rosenkrantz et al., 1981) 
Human THC General Toxicity (Brill et al., 1970) 
  Neurology (Fusar-Poli et al., 2009) 
  Fertility (Lewis et al., 2012) 
 CBD Physiology; Neurology 
(Cunha et al., 1980; 
Fusar-Poli et al., 2009) 
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1.5 RT-qPCR and Genes of Interest 
 In this study, embryos/larvae were collected from across the concentration-
response curve and treatments after 14, 24, 48, 72 and 96 hpf for RT-qPCR analyses of 
the selected genes. Each time point represents a key developmental stage in 
morphogenesis and neurogenesis signaling that may be disrupted by cannabinoid 
exposure (Grossman et al., 2010). We hypothesized that altered expression of bdnf (Collo 
et al., 2014), c-fos (Stranahan et al., 2013), and reln (Folsom and Fatemi, 2013; L. Wang 
et al., 2006) were indicative of neurotoxicity. Key morphology and reproductive biomarker 
genes include sox2, sox3, and sox9a (Bal-Price et al., 2015; Fang et al., 2010), vasa 
(Williams et al., 2014) and dazl (Li et al., 2016). Cannabinoid receptors (cnr1 and cnr2) 
(Krug and Clark, 2015)) were measured to determine if exposure altered their basal 
expression. Primer sequences and primer optimization information can be found in Table 
2.1. 
 
1.5.1 c-fos 
 c-fos is primarily expressed in the zebrafish brain (Baraban et al., 2005) and well-
established biomarker for characterizing neuronal activity, which is particularly critical 
when studying the therapeutic potential of novel anti-seizure drugs. c-fos is also a 
potential mitogenic marker; however, research is inconclusive in this area. One of the 
original studies to research c-fos in depth was by Morgan et al., 1987; wherein they 
mapped the patterns of c-fos during seizure events, and used known anti-seizure 
medication to elucidate c-fos expression profiles. The results indicated that c-fos mRNA 
expression was directly correlated to PTZ seizure stimulation from 15 minutes to as late 
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as 180 minutes and also in a concentration-dependent manner from 0 mg/kg to 50 mg/kg 
(Morgan et al., 1987). In addition, studies were conducted to assess the effect of known 
anti-seizure medications such as diazepam on the expression of c-fos. Following PTZ 
treatment, diazepam effectively reduced c-fos mRNA expression while a DMSO/PTZ 
exposure proved to be ineffective (Morgan et al., 1987). Since this report, the use of c-
fos in zebrafish (Afrikanova et al., 2013; Baraban et al., 2005; Ellis et al., 2012; Rahn et 
al., 2015; Ruhl et al., 2014) and mice (Buenafe et al., 2013; Morgan et al., 1987; Sonego 
et al., 2016), primarily as a marker of seizure-like molecular attributes was confirmed.  
 
1.5.2 bdnf 
 Neurodevelopment through early developmental stages, and cognitive decline 
later in life have both been correlated with bdnf expression and signal transduction 
(Angelucci et al., 2010; De Felice et al., 2014). This especially holds true for neuronal 
degeneration and plasticity, which potentially affect cognitive functions such as, learning 
and memory, social interaction, and mental health (Angelucci et al., 2010; Bekinschtein 
et al., 2008; Budni et al., 2015; Cunha et al., 2009). bdnf is expressed throughout the 
mammalian, human, and zebrafish CNS with prominent presence in brain regions (Budni 
et al., 2015; Cacialli et al., 2016; De Felice et al., 2014; Maisonpierre et al., 1990). 
Analysis of bdnf expression in both larval (whole body homogenate) and adult zebrafish 
(brain tissue homogenate) will help identify potential adverse effects on both the 
developing, adolescent, and aging brain, which could be directly correlated with 
behavioral phenotypes such as, developmental neurotoxicity (larval light:dark analysis) 
(Kirla et al., 2016), learning and memory (T-maze) (Braida et al., 2014), social interaction 
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(shoaling behavior) (Grossman et al., 2010), and mental health i.e., anxiety (novel tank 
test  (Kyzar et al., 2013) and open field (Grossman et al., 2010)).   
 
1.5.3 dazl and vasa 
 Maintaining germline stability across generations is imperative for reproductive 
fitness. Our molecular marker for tracking the status of germline function was deleted-in-
azoospermia-like (dazl) gene which is among the larger Daz family of genes (Li et al., 
2016). dazl, along with other genes and factors, is imperative for primordial germ cell 
maturation, which is critical for the development of both spermatozoa and oocytes. These 
genes are maternally inherited and concentrate early in development in the upper yolk 
sac of zebrafish (Hashimoto et al., 2004). Measuring the expression of dazl from early 
development (14 hpf) through adulthood in the F0 and F1 generation will allow us to 
directly track the maintenance of the germline in a dazl-dependent manner. Contrary to 
p-element induced wimpy testis (piwi) RNA which is essential for male germ cell 
development (Tan et al., 2002), vasa is critical for germ call development in females 
(Anderson et al., 2007). Studies have observed DAZL and VASA proteins co-localized 
and working in concert with one another in the maturation of germ cells regardless of sex 
(Anderson et al., 2007).  
 
1.5.4 sox2, sox3, reln 
 Similar to bdnf, sex determining region Y-box (sox2) is a transcription factor 
involved in many pathways connected with neuronal development as well as cognitive 
impairment such as learning and motor dysfunction to seizures (Kelberman et al., 2006; 
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Sisodiya et al., 2006). Complete loss of sox2 expression was directly associated with 
multiple eye development disorders like microphthalmia and anophthalmia (Hever et al., 
2006). Another more general transcription factor, sox3¸is also involved with neuronal 
development (Dee et al., 2008), and is critical for the transition of both neuronal and non-
neuronal fate stem cells (Dee et al., 2007). Studies in zebrafish have shown exogenously 
expressed sox3 to form tissue with neuronal characteristics (Dee et al., 2007). Lastly, reln 
has been associated with various cognitive disorders such as autism (Fatemi et al., 2005) 
and schizophrenia (Fatemi, 2001). Mice carrying reln mutations experience numerous 
neurodevelopmental phenotypes from incorrectly placed neurons to cerebellar 
hypoplasia (Goffinet, 1984).  
 
1.5.5 krit1, sox9 
 Genes that are critical for specific developmental endpoints include cerebral 
cavernous malformations gene or (krit1) which is important for the development of smooth 
muscle cells and organization of cardiac tissue. krit1’s expression was expected to 
correlate with malformed cardiac chambers (Chen et al., 1996; Wüstehube et al., 2010). 
Specifically, due to the increased incidence of pericardial edemas observed in zebrafish 
exposed to THC and CBD, and what seemed like a disorganization or lack of heart 
morphology, krit1 was screened.. sox9 is another transcription factor that is important for 
the formation of bone and cartilage (Yan et al., 2005). Zebrafish mutants lacking sox9, 
reveal a specific phenotype of an inwardly curved axis. This inwardly curved axis is not 
typically observed by our lab during morphology screening; however, these mutants are 
 31 
 
also characterized by a significant jaw dysmorphology (lack of a jaw), which is commonly 
observed (Yan et al., 2005).  
 
1.5.6 18s 
 Ribosomal RNA (18s) is a well-established, stable reference gene used to carry 
out RT-qPCR analysis (Bas et al., 2004; Filby and Tyler, 2007; McCurley and Callard, 
2008; Tang et al., 2007; Y. Wang et al., 2006).  
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1.6 Aims and Hypothesis Statement 
 The goal of this project was to study the reproductive and developmental toxicity 
of THC and CBD using zebrafish as a highly relevant, predictive, and high-throughput 
model. Specifically, we aimed to establish a zebrafish model for developmental exposure 
to THC or CBD and scrutinize the resulting differential gene expression, developmental 
deformities, behavioral alterations, and decreased reproductive success. Initially THC 
was expected to have adverse side-effects on brain development and gamete viability, 
but little was known about the toxicity of CBD. Our central hypothesis in Aims 1 and 2 
was that developmental exposure to CBD or THC changes gene expression in critical 
morpho-/neurogenesis genes during development that are, in turn, related to the origins 
of adult disease.  
 Our experimental approach was accomplished in two research aims and one 
analytical aim. Aims 1 and 2 are diagramed in Figure 1.2. Briefly, F0 fli transgenic 
zebrafish were exposed to THC, CBD, or DMSO (Figure 1.5). Across the cannabinoid 
dose-response, we measured morphological and behavioral abnormalities throughout 
development and at a few time points on the whole transcriptome. Tissue- and 
developmental-stage specific gene expression of key morphogenesis and 
neurodevelopmental genes hypothesized to be biomarkers of toxicity were measured at 
multiple time points (14, 24, 48, 72, and 96 hpf) by RT-qPCR. After the initial 96 hr 
exposure, fish were allowed to grow for 6 months with no further treatment. In adults, we 
measured potentially compromised learning and anxiety behaviors (12-18 months; Aim 
1) and reproductive success (6 months; Aim 2) The same morphological, behavioral, and 
gene expression studies were carried out with F1 embryos at the same time points as F0. 
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Aim 3 used zebrafish to develop a toxicokinetic model for cannabis exposures in an 
aqueous medium. Extraction methods for plasma and urine are easily accessible (Kemp 
et al., 1995) in many animal models; however, methods for extracting THC or CBD from 
water using aquatic organisms was lacking. 
 
Figure 1.5 Experimental flow chart. Embryos were collected at ~1 hpf and cleaned/sorted 
into glass vials. Regardless of the exposure duration, all embryos were handled and 
exposed similarly. 14, 24, 48, and 72 hpf time-points were analyzed for survival then 
collected for RT-qPCR, while 96 hpf larvae were transferred to a 96-well plate and 
screened for morphological and behavior abnormalities. Following morphological and 
behavior screening, 96 hpf were also collected for RT-qPCR.   
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 Our overall goal of Aims 1 and 2 is to establish the continuum of THC and CBD-
mediated initiating event(s) followed by related anatomic and functional adverse 
outcomes which, in turn, impact individual and population level incidences of disease 
(Ankley et al., 2010). As is depicted in the Figure 1.1 AOP scheme, our plan was to 
quantitatively assess biomarkers at the macromolecular, cellular, organ, organism and 
population levels of biological organization in order to generate a mechanism-based 
dose-dependent understanding of cannabinoid developmental toxicity.  
 The focus of this work was on the embryo-larval stage of development. There are 
several logistical and physiological justifications for this initial focus. For example, 
embryos are easy to expose and only small amounts of chemical are needed. Developing 
organisms are especially susceptible to toxicants, and thus, statistically significant 
alterations in gene expression and phenotype are easier to measure and causatively 
associate during development. These studies will then inform future experiments where 
more chronic exposure regimes and/or later developmental (e.g. puberty or adult 
equivalent) stages could be exposed in order to align our approach more closely to model 
epilepsy patients and other users of medical marijuana. To test our central hypothesis of 
CBD toxicity we will conduct the following three specific aims: 
 
1. Compare key gene expression, behavioral changes, and developmental 
abnormalities in developing zebrafish and in their subsequent offspring.  
 Hypothesis: CBD and THC will alter gene expression in unique ways that 
mechanistically support phenotypic defects. Differential gene expression will persist in 
F1 offspring without additional exposure.      
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 Approach:  Developmentally expose zebrafish embryos/larvae to CBD or THC and use 
RT-qPCR to quantitate concentration-dependent, developmental stage- gene 
expression in important neurodevelopmental and morphological genes in F0 and F1 
fish at 14, 24, 48, 72 and 96 hpf. Measure developmental deformities and behavioral 
changes in 96 hpf F0 & F1 larvae as well as F0 adult behavior. 
2.  Measure reproductive consequences of a developmental exposure to THC and 
CBD. 
 Hypotheses: Developmental exposure to cannabinoids will compromise adult 
reproductive success in a sex-dependent manner and gamete health will be dose-
dependently decreased after THC exposure. THC will be a more potent reproductive 
toxicant as compared to CBD. 
 Approach: (a) Assess the hatching time, fertilization success, and mortality of F1 
offspring from parents that were developmentally exposed to THC or CBD. (b) 
Determine dose-dependent effects of cannabinoid developmental exposure on adult 
fecundity. 
3. Establish analytical toxicokinetic parameters for the conducting of water-based 
cannabinoid exposures using zebrafish.  
 Hypothesis: THC and CBD will decrease over time in our static water exposure, but 
increase over time in tissue (bioconcentrated).  
 Approach: (a) Establish a liquid:liquid extraction method for removing THC or CBD 
from both water and tissue prior to GC-MS analysis. (b) Measure THC and CBD 
concentrations in zebrafish embryo medium and whole tissue homogenate directly 
following water dosing (time 0 hr) through experiment termination (time 96 hr).    
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 Successful completion of these aims will establish for the first time the potential 
selective toxicity of THC versus CBD as a developmental, reproductive, and behavioral 
toxicant. This work is highly relevant because human exposure to THC is known to cause 
reproductive deficits including: pregnancy loss and sperm malformations (Lewis et al., 
2012; Nahas et al., 2002) and in children, brain development deficits and social disorders 
(Crean et al., 2011; Solowij et al., 2012; Szutorisz et al., 2014; Tortoriello et al., 2014; Wu 
et al., 2011). However, the developmental toxicity of CBD is unknown. Zebrafish are a 
well-established model in developmental biology, toxicology testing, and increasingly 
used for high-throughput screening in drug development (Feitsma and Cuppen, 2008; Hill 
et al., 2005; Kalueff et al., 2014; MacRae and Peterson, 2015; Padilla et al., 2012; Pei 
and Strauss, 2013; Tobia et al., 2013; Vitale et al., 2014). Through this work, we will gain 
insight into the potential mechanisms mediating both cannabinoid toxicity and therapeutic 
efficacy.  
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CHAPTER 2 DEVELOPMENTAL EFFECTS OF CANNABIDIOL AND Δ9-
TRETRAHYDROCANNABINOL IN ZEBRAFISH 
2.1 Abstract 
 Cannabidiol (CBD) has gained much attention in the past several years for its 
therapeutic potential in the treatment of drug-resistant epilepsy, such as Dravet 
Syndrome. While CBD has shown anecdotal efficacy in reducing seizure frequency, little 
is known regarding the potential adverse side-effects of CBD on physiology, 
development, organogenesis, or behavior. The goal of this chapter is to compare the 
relative morphological, behavioral, and gene expression phenotypes resulting after a 
developmental exposure to Δ9-tetrahydrocannabinol (THC) or CBD. Zebrafish were 
exposed from blastula through larval stage (96 hour post fertilization) to 0.3, 0.6, 1.25, 
2.5, 5 mg/L (1, 2, 4, 8, 16 μM) THC or 0.07, 0.1, 0.3, 0.6, 1.25 mg/L (0.25, 0.5, 1, 2, 4 μM) 
CBD. Despite the similarity in THC and CBD dysmorphologies, i.e., edemas, curved axis, 
eye/snout/jaw/trunk/fin deformities, swim bladder distention, and behavioral 
abnormalities, the LC50 for CBD (0.53 mg/L) was nearly seven times lower than THC (3.65 
mg/L). At 96 hpf, c-fos, dazl, and vasa were differentially expressed following THC 
exposure, but only c-fos expression was significantly increased by CBD. CBD was more 
bioconcentrated compared to THC despite higher THC water concentrations. This work 
supports the potential for persistent developmental impacts of cannabinoid exposure, but 
more studies are needed to assess latent effects and their molecular mechanisms of 
toxicity. 
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2.2 Introduction 
Cannabidiol (CBD) has gained much attention in the past several years for its 
therapeutic potential in the treatment of many ailments, including tragic forms of drug-
resistant epilepsy, such as Dravet Syndrome (Devinsky et al., 2017). Additionally, CBD 
legalization is increasing in the United States due to potential therapeutic indications 
ranging from depression, schizophrenia, chronic pain, and even cancer (McKenna, 2014). 
Medical cannabis legalized states, such as Washington, currently offer over 800 CBD 
products available for purchase, and CBD sales in the United States are projected to 
reach $2.1 billion by 2020 (Murphy and Ooyen, 2016). Numerous studies suggest CBD 
contains therapeutic potential (Cridge and Rosengren, 2013; Devinsky et al., 2017, 2014); 
however, the toxicology community has yet to scrutinize its possible adverse effects. Most 
importantly, CBD is currently being administered to toddler through adult aged patients of 
Dravet Syndrome, with little empirical evidence of its potential developmental or 
reproductive consequences. Moreover, CBD is perceived to possess a safer toxicological 
profile than Δ9-tetrahydrocannabinol (THC) due to its weak affinity for cannabinoid 
receptor 1 (CB1); therefore, lacking a psychotropic effect. This study aimed to define the 
relative adverse developmental effects of CBD compared to the more well-known 
cannabis constituent, THC, which does cause reported developmental, teratogenic, and 
behavioral abnormalities (Akhtar et al., 2013; Becker et al., 2010a; Brunet et al., 2006; 
Crane et al., 2013; Deiana et al., 2012; Fontes et al., 2011; Geber and Schramm, 1969; 
Hisaoka, 1958; Hurd et al., 2005; Maccarrone and Finazzi-Agro, 2004; Paria et al., 1995; 
Ruhl et al., 2014; Stewart and Kalueff, 2014; Thomas, 1975; Wright et al., 1976).       
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The EDC and its corresponding G-protein coupled receptors, CB1 and CB2, are 
critical for early development and central nervous system maturation (Psychoyos et al., 
2012). Disruption of the EDC can effect early developmental stages leading to 
dysmorphologies, embryotoxicity, behavioral abnormalities, memory deficits, and 
adverse neurogenesis in zebrafish, chick, rodents, and humans (Harbison et al., 1977; 
Paria et al., 1995; Psychoyos et al., 2012; Watson et al., 2008). Distribution of 
cannabinoid receptors differ; in vertebrates CB1 is currently thought to primarily 
concentrate in the central and peripheral nervous systems while CB2 is primarily 
expressed in the immune system (Lam et al., 2006; Pertwee, 2006). Although much 
debate encompasses the individual actions of CB1 and CB2 signaling, CB1 receptors 
have been connected to cardiovascular activity, neuroplasticity, olfaction, and GABA(A) 
signaling (Tortoriello et al., 2014). CB2 functions are less known, but include immune 
regulation and potential adversities related to neurodegeneration (Szaflarski and Martina 
Bebin, 2014). The EDC amongst mammals and zebrafish is highly conserved (Krug and 
Clark, 2015). Whole-larval homogenate has shown CB1 mRNA expression present during 
the 3 somite stage through the 25 somite stage (B. Migliarini and Carnevali, 2009), while 
whole-mount in situ hybridization localized CB1 mRNA throughout the zebrafish brain 
with highest expression in the telencephalon at 96 hpf (Lam et al., 2006). In addition, CB1 
protein has been observed in both larval zebrafish brain homogenates beginning around 
48 hpf through 15 days post fertilization (B. Migliarini and Carnevali, 2009). CB2 has also 
been detected throughout the adult zebrafish gills, heart, retina, intestine, spleen, brain, 
and pituitary, less is known regarding CB2’s expression patterns throughout development 
and adolescence (I. Rodriguez-Martin et al., 2007). 
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Signal transduction with regard to THC, CBD, and the EDC are still under 
investigation; however, an important mechanistic role in the propagation and 
maintenance of seizures in animal models and humans has been reported (Consroe et 
al., 1982, Consroe & Wolkin, 1977, Devinsky et al., 2017, & Jones et al., 2010). The 
primary exogenous ligand of CB1 is THC; however, CBD has low affinity for CB1. Instead 
CBD preferentially binds to CB2 and may actually possess antagonistic properties toward 
CB1 (Schönhofen et al., 2015). Because of the recognized roles of endogenous ligands 
such as 2-AG , AEA, and the cannabinoid receptors in neurodevelopment (reviewed in 
Basavarajappa et al., 2009), it is imperative to uncover possible mechanisms of CBD 
and/or THC toxicity during essential stages of neurodevelopment and organogenesis. 
Dating back to the 1960’s, animal models have been used to elucidate cannabinoid 
toxicity (Persaud and Ellington, 1968). Primary literature has focused on prenatal and 
postnatal exposure in rodents via oral or subcutaneous injection measuring various 
endpoints from behavior and endocrine function to neuropathology (Scallet, 1991). 
Adverse outcomes in rodents of developmental exposure include craniofacial (Bloch et 
al., 1986) and behavior abnormalities (Onaivi et al., 1995; Wright et al., 1976) similar to 
those reported in zebrafish (Akhtar et al., 2013; Thomas, 1975), but very few publications 
offer insight into CBD toxicity. Recent literature has primarily focused on the protective 
and therapeutic potential of CBD; however, some results suggest that CBD exposure 
during neuronal development might lead to sensitization to neurotoxicants (Schönhofen 
et al., 2015). Rats and adult zebrafish were used to demonstrate CBD’s behavior 
abnormalities (Nazario et al., 2015a; Resstel et al., 2009), but little information has been 
offered with regard to developmental adversities, potential onset of adult disorders, or 
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early neurogenesis and maturation which may result from a teratogenic or pediatric 
exposure.  
The goal of this project was to use the highly relevant zebrafish model to study the 
potential morphological and behavioral toxicities of CBD compared to a known 
developmental toxicant, THC (Akhtar et al., 2013; Thomas, 1975). Developmental 
biomarkers were also screened to elucidate potential mechanistic roles. Additionally, we 
provide evidence that via water-based exposures, lipophilic cannabinoids (THC log P: 
6.97; CBD log P: 5.79) bioaccumlated in fish embryos (Thomas et al., 1990) and caused 
developmental toxicity.  
 
2.3 Material and Methods  
2.3.1 Zebrafish Care and Exposure 
Tg(fli1:egfp) zebrafish were purchased from Zebrafish International Resource 
Center (ZFIN, Eugene, Oregon). Healthy adult zebrafish were placed in aerated breeding 
units containing water from an Aquatic Habitats Zebrafish Flow-through System (Aquatic 
Habitats, Apopka, Florida), pH 7.5-8.0, dissolved oxygen 7.2-7.8 mg/L, conductivity 730-
770 μS, temperature 27°-29°C. The next morning, eggs were collected, debris removed, 
and randomly sorted into scintillation vials (n = 3 vials; 10 embryos per vial) containing 
embryo water (sterilized deionized water; pH of 7.4-7.7; 60 parts per million (ppm) Instant 
Ocean, Cincinnati, Ohio). Scintillation vials were then placed into a stand-up incubator at 
27°-29°C. Exposed eggs were screened every 24 hours to assess overall health and to 
remove any dead embryos. All culture and exposure protocols were in accordance with 
approved IACUC guidelines and recommendations. At ~2 hpf, original transfer water was 
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removed and replaced with 0.3125, 0.625, 1.25, 2.5, 5 mg/L (1, 2, 4, 8, 16 μM) THC 
(0.05% DMSO), 0.075, 0.15, 0.3, 0.6, 1.2 mg/L (0.25, 0.5, 1, 2, 4 μM) CBD (0.05% 
DMSO), or 0.05% DMSO control water. Embryos were exposed in scintillation vials at a 
0.6:1 (mLs water:fish) ratio in static conditions without a water change during the 
exposure period. Every 24 hours, mortalities, debris, and sloughed chorions were 
removed from vials. THC and CBD were provided by the NIDA Drug Supply Program 
(DEA License #RW0497796). 
 
2.3.2 Morphological and Behavior Screening  
At 96 hpf, larvae were transferred from scintillation vials into 96-well plates (one 
larvae per well). Touch response, yolk sac and pericardial edema, axis curvature, 
eye/snout/jaw/trunk deformities, swim bladder inflation, and pectoral fin dysmorphologies 
were all qualitatively analyzed single-blinded as either deformed (yes) or not deformed 
(no). LC50 values were calculated using the EPA’s LC50 calculation program at the 
conclusion of the 96 hpf assessment (Hamilton et al., 1977). Lowest observed adverse 
effect levels (LOAELs) were calculated as a 20% dysmorphologic occurrence greater 
than controls (e.g. if curved axis occurrence in control fish was 5%, the LOAEL 
concentration = ≥ 25% curved axis occurrence). Following morphological screening, 
zebrafish with a touch response were directly transferred to an isolated behavioral 
screening room kept in full light at 27°-29°C and allowed to acclimate for 5 minutes. Touch 
response was assessed by touching the larvae’s tail with the end of a 10 μl pipette tip. 
Larvae either reacted to the mechanical impact by avoidance swimming or did not 
respond. Zebrafish were then monitored using a ViewPoint ZebraBox (ViewPoint, 
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Montreal, Canada) for 30 minutes (0-10 min, 100% light (8000 lux); 10-20 min, dark, 0% 
light; and 20-30 min, 100% light) (Kirla et al., 2016). Travel duration at a velocity ≥5 
mm/sec was collected per well and averaged per dosing parameter. Duration mean for 
each pooled vial was calculated and statistical significance was calculated per vial (n = 
3) using two-way analysis of variance with repeated measure followed by Bonferroni post 
hoc test (p ≤ 0.05) (n = 3 replicates; 7-10 larvae per replicate for morphology screen and 
n = 6 – 30 for behavioral screens). THC (1.25 mg/L) and CBD (0.3 mg/L) were excluded 
from statistical analysis due to a lack of fish (n < 3) healthy enough to perform in the 
behavioral analysis; however, they are still depicted in Figure 2.     
  
2.3.3 RT-qPCR 
Following the behavioral screen, larval zebrafish were pooled (n = 3 vials; 10 fish 
per vial) in RNAlater and stored at -80°C until RNA isolation and processing. Whole larval 
RNA was isolated utilizing TRIzol (Invitrogen #A33251), RNase-Free DNase set (Qiagen 
#79254), and RNeasy micro kit (Qiagen #74004) according to manufacturer’s protocol. 
Extracted RNA was then quantified and assessed for acceptable 260:280 ratio on a 
NanoDrop 2000 followed by cDNA (10 μg/μL) sub-stock preparation (Invitrogen 
#4304134). RT-qPCR was performed on an Applied Biosystems 7200 using SYBR Green 
chemistry (Applied Biosystems #4309155) with the following parameters: 95°C for 10 min, 
then 40 cycles of 95°C for 15 sec and 60°C for 1 min, followed by 95°C for 15 sec-60°C 
for 1 min-95°C for 15 sec dissociation curve. Primer optimization and confirmation was 
performed as previously described in Fang et al., 2013. Final concentrations in the 
reaction mix were: forward and reverse primer 0.2 μM, template cDNA 0.4 ng/μL, and 
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SYBR Green PCR Master Mix according to manufacturer’s protocol (Applied 
Biosystems). All samples (n = 3) were screened in duplicate and evaluated using the 2-
ΔΔCT method (Livak and Schmittgen, 2001). RT-qPCR results were analyzed using three 
pooled (10 fish) homogenate biological replicates (n = 3). For statistical significance, we 
used one-way analysis of variance followed by Tukey’s post hoc test with statistical 
significance being met at p ≤ 0.05. Additional RT-qPCR information available in 
Supplemental Table 2.1. 
 
2.3.4 GC-MS Analysis  
In order to confirm exposure concentrations and better understand the exposure 
kinetics of THC and CBD, water and tissue concentrations were verified at 0 hpf (Ti) and 
96 hpf (Tf), as previously described (Kudo et al., 1995). Briefly, deuterated THC-d3 (Sigma 
Aldrich) was added to 2 mL (10 mg/L) of exposure water along with 1 mL of 2 M NaOH 
followed by a solvent:water extraction using hexane:ethyl acetate (9:1, v/v) repeated two 
times. Once in solvent, samples were evaporated to dryness using nitrogen in a water 
bath at 55°C. Samples were then reconstituted and derivatized in N,O-
Bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane (Thermo Scientific) at 
90°C for 1 hour. Following derivatization, samples were evaporated to dryness and 
reconstituted in 50 μL isooctane and transferred directly to the GC-MS (Agilent 
Technologies 6890N; Mass Spectrometer 5973) with DB-5MS column (Agilent 
Technologies)  for analysis as previously described (Kemp et al., 1995). Retention times 
and ions [quantitatve;qualitative] for quantifying THC-d3, THC, and CBD were as follows: 
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8.142 min [374;389 m/z], 8.167 min [386;371 m/z], and 6.936 min [390;458 m/z]. Our 
lowest observed quantifiable concentration was 8 μg/L THC and 19 μg/L CBD. 
For tissue extractions, dry larvae were weighed and then homogenized in 
hexane:ethyl acetate (9:1, v/v) (containing THC-d3) with 100 pulses of a teflon pestle. 
Following homogenization, extractions were evaluated as described above for water. 
Measured water and tissue concentrations of THC or CBD were calculated using a 
relative response factor derived from the surrogate standard recovery (e.g. [initially 
measured THC or CBD concentration/surrogate standard recovery]). Bioconcentration 
factors were calculated by dividing the measured concentration of compound in tissue 
samples at 96 hpf by the measured concentration of compound in exposure water at 0 
hpf, bioconcentration factor (BCF=Ctissue(Tf) / Cwater(Ti)). To measure extraction recoveries 
pooled whole zebrafish larvae (n = 10 per replicate; 2-10 replicates) at 96 hpf and 
hexane:ethyl acetate (9:1, v/v) were spiked with 10 mg/L THC, CBD, or THC-d3, and then 
extracted as described above. Recoveries were calculated by comparing the area under 
the curve (AUC) of ion peaks to a non-extracted standard curve 0.016 mg/L to 50 mg/L 
for each compound. Recoveries were as follows: THC 83.7 ± 11.6%; CBD 54.2 ± 0.14%; 
and THC-d3 65.5 ± 8.6%.   
 
2.3.5 Statistics 
 All statistical analysis was analyzed in GraphPad Prism 5.0. Data analysis included 
as appropriate, normal theory (e.g. ANOVA) and/or non-parametric (e.g. Kruskall-Wallis) 
procedures to test treatment-related effects. Behavioral phenotypes were analyzed using 
two-way ANOVA with repeated measures followed by Tukey’s post hoc test. In the event 
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of RT-qPCR not achieving statistical significance after one-way ANOVA and Tukey’s post 
hoc analysis, data was subjected to an unpaired student’s t-test. p < 0.05 will be used as 
the cut-off for statistical significance. 
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Table 2.1 RT-qPCR Primers   
Gene Accession Primer sequence r2 
Efficiency 
% 
c-fos BC065466 
F: 5'-CAC CGA TAC ACT GCA AGC TGA A-3' 
R: 5'-CAG GTT GGC GAT GTC GTT CT-3' 
0.997 106.2 
dazl BC076423 
F: 5'-AAT GCC CAG CTT GCC TAA TG-3' 
R: 5'-CAC GCG GCC GAA ACC-3' 
0.974 84.06 
vasa AF461759 
F: 5’-CAG ACA AGT TGG ATC AAG AAG GAA-3’ 
R: 5’-GGC GGC GGC ACA TAA AC-3’ 
0.971 92.35 
sox2 BC065656 
F: 5'-ACC AAC TCG CAG ACC TAC ATG A-3' 
R: 5'-GCG TGC TTT GCT GCG AAT-3' 
0.988 100.42 
sox3 AB117960 
F: 5'-CCG GCC ATA ACC TCT CAC TCT-3' 
R: 5'-GGC GGC AGG TAC ATG CTT-3' 
0.999 94.99 
sox9a BC093134 
F: 5’-CAT CCC TCA ATC CAA CCA CAG-3’ 
R: 5’-GGT CTG GAC AGC TGC GTG TAC-3’ 
0.938 87.08 
krit1 BC055149 
F: 5’-CAT AAT AGG GAA GCG TGT TGT G-3’ 
R: 5’-GGA GGA GAA ATG AGC ACT GG-3’ 
0.992 75.8 
bdnf BC058301 
F: 5’-GAC TCG AAG GAC GTT GAC CTG TA-3’ 
R: 5’-CGG CTC CAA AGG CAC TTG-3’ 
0.977 97.95 
reln JF693485 
F: 5’-TTC TAC TGC CCC TAC CAG AGA G-3’ 
R: 5’-AAT CTC GAG AAA ACT CCA GAC G-3’ 
0.930 84.12 
cnr1 AY148349 
F: 5’-TGT GGG AAG CCT GTG TTC TCA CT-3’ 
R: 5’-CGA TGC GCC GGT ACG A-3’ 
0.920 86.36 
cnr2 AY263391 
F: 5’- TCT AGC CGG CCC AGT GAC T-3’ 
R: 5’- GTG CTG TGG AGC TTG CAA TG-3’ 
Not functional 
18s FJ915075 
F: 5'-TGG TTA ATT CCG ATA ACG AAC GA-3' 
R: 5'-CGC CAC TTG TCC CTC TAA GAA-3' 
 
0.999 75.61 
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2.4 Results 
2.4.1 Water and Tissue Analysis 
 Actual THC concentrations in water at Ti (0 hpf) were between 64-88% of 
expected and declined to between 16-32% of Ti at 96 hpf (Tf) (Table 1). Actual CBD 
concentrations were only 33-40% of nominal at Ti and decreased to either not detected 
or 3% of Ti at Tf (Table 2.2). THC and CBD tissue concentrations were assessed at 96 
hpf following homogenization and solvent extraction. Following 96 hpf exposure to 0.313 
or 1.24 μg/mL THC, the calculated BCF’s were approximately 1.4 and 0.65, respectively 
(Table 2.2). Following 96 hpf exposure to 0.075 or 0.3 CBD, the calculated BCF’s were 
39 and 790, respectively (Table 2.2). After 96 hr of exposure to nominally 0.3 μg/ml THC 
or CBD, tissue concentrations in larvae were 0.28 μg/g and 79 μg/g, respectively. 
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Table 2.2 Water and Tissue Concentrations.      
Compound hpf 
Nominal Water 
Concentration 
Measured 
Water 
Concentration 
% Nominal  Fish Massb 
Measured Tissue 
Concentration   
BCFc 
   μg/mL μg/mL ± SD   g ± SD μg/g ± SD   
Δ9-
Tetrahydrocannabi
nol           
  
  
  0 0a nd -      
   0.313 0.2 ± 0.01 64      
   1.25 1.1 ± 0.2 88      
  96 0a nd - 0.01 ± 0.0 nd - 
   0.313 0.05 ± 0.008 16 0.007 ± 0.001 0.28 ± 0.14 1.4 
   1.25 0.4 ± 0.03 32 0.001 ± 0.008 0.71 ± 0.72 0.65 
Cannabidiol               
  0 0a nd -      
   0.075 0.03 ± 0.01 40      
   0.3 0.1 ± 0.03 33      
  96 0a nd - 0.003 ± 0.003 nd - 
   0.075 nd - 0.002 ± 0.0 1.2 ± 0.16 39 
    0.3 0.01 ± 0.004 3 0.003 ± 0.001 79 ± 51 790 
nd = not detected        
a Control (0.05% 
DMSO)        
b 3 - 7 larvae        
c BCF = Ctissue(time 96) / Cwater(time 0)       
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2.4.2 Lethality and Morphology 
Following a waterborne exposure to CBD and THC, 96 hpf zebrafish displayed 
concentration-dependent morphological (Figure 2.1) and behavioral toxicities (Figure 
2.2). The CBD LC50 of 0.53 mg/L was nearly seven times lower than that of THC (3.65 
mg/L). CBD and THC shared similar adverse morphologic outcomes, i.e., yolk sac and 
pericardial edema, pectoral fins missing, and swim bladder distention; however, the 
LOAEL for these observed dysmorphologies varied (Figure 2.1). For example, the LOAEL 
for pericardial edema following THC exposure was approximately 0.6 mg/L, while CBD 
was more than ten times lower at 0.07 mg/L (Figure 2.1). Similarly, LOAELs for jaw 
malformations (5 mg/L THC, 0.3 mg/L CBD), axis curvature (2.5 mg/L THC, 0.6 mg/L 
CBD), and trunk degradation (2.5 mg/L THC, 0.6 mg/L CBD) were all lower in CBD 
exposed larvae compared to THC.   
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Figure 2.1 THC and CBD morphologic phenotypes. Following 96 hpf exposure to THC or 
CBD larvae were plated in 96-well plates (one per well) and qualitatively assessed for 
common developmental dysmorphologies. All morphology endpoints were designated 
either a yes (abnormal) or no (normal) and quantitatively calculated from the total larvae 
measured for both THC (A) and CBD (B). Higher concentrations with 100% occurrence 
in all endpoints are depicted. Subsequent phenotypical pictures were taken following the 
morphology screening (C), red arrows indicate a few key morphologic endpoints (T = 
trunk, A = axis, SB = swim bladder, P = pericardial edema, Y = yolk sac edema). In 
addition to phenotypic malformations following 0.6 mg/L CBD exposure, we also observed 
numerous 96 hpf larvae that were unhatched. Heat-map portrayal (D) of the LOAEL after 
96 hpf exposure to THC and CBD (n = 3 replicates consisting of 10 fish per replicate). 
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2.4.3 Behavior 
Behavior is assessed via movement during dark conditions compared to bright light 
conditions. Typically, zebrafish larvae exhibit hyperlocomoter behavior during dark 
periods and hypolocomoter behavior during bright conditions, especially during initial 
cycling periods (Kirla et al., 2016). Larvae exposed to 0.3 mg/L THC or 0.07 mg/L CBD 
exhibited a significantly increased duration of movement (seconds of duration ≥ 5 
mm/sec) during dark periods compared to control. In contrast, 1.25 mg/L THC and 0.1-
0.3 mg/L CBD significantly reduced duration compared to control, which is indicative of 
hypolocomoter activity (Figure 2.2). All duration times were compared using two-way 
ANOVA with the Bonferroni post-test ± SEM. All larvae lacking a touch response or 
phenotypically not able to swim were excluded from behavioral assessment; therefore, 
high concentrations of compound tended to result in smaller sample sizes (n = 6-30) 
which lead to increased standard errors. However, even with increased error, larvae 
exposed to 1.25 mg/L THC still exhibited significantly decreased duration during dark 
periods compared to control larvae (minute 16; Figure 2.2). 
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Figure 2.3 Larval zebrafish behavioral heat map. Larval zebrafish behave in a consistent 
manner when subjected to alternating light phases. Hypolocomotor activity is a result of 
a normal phenotype during lit periods (top), while hyperlocomoter activity is a normal 
phenotype during dark periods (bottom). The tracking lines of the ZebraBox allow us to 
discern between different velocities of movement, i.e., inactive (black), slow (green), and 
fast (red).   
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Figure 2.2 THC and CBD larval behavior. Zebrafish larvae at 96 hpf were monitored using 
a ViewPoint ZebraBox for 30 minutes (0 – 10 min, light: 10 - 20 min, dark (grey box): 20 
– 30 min, light). Duration of movement (seconds) at a velocity ≥ 5 mm/sec was collected 
at 2 min intervals and compared to control. Behavioral assessment was specific only to 
larvae displaying a touch response and uninhibited phenotypes; therefore, the full range 
of concentrations-response is not available. Larvae exposed to 0.3 mg/L THC exhibited 
significant (*) hyperlocomoter activity compared to control in dark periods (minutes 12-
20); however, 1.25 mg/L THC reduced overall duration of movement at minute 16. 
Similarly, CBD significantly stimulated locomotor activity at 0.07 mg/L, but larvae exposed 
to 0.1 and 0.3 mg/L CBD exhibited hypolocomoter characteristics. Data were analyzed 
on the average distance per vial (n = 3) using two-way ANOVA with repeated measure 
followed by Bonferroni post-test ± SEM (p ≥ 0.05). (n = 3 vials; 7-10 larvae per vial). 
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2.4.4 RT-qPCR 
 Following a 96 hpf exposure to THC or CBD, larval zebrafish were screened for 
potential differential expression of ten key morphogenic or neurogenic genes. c-fos was 
differentially up-regulated in a concentration-dependent manner following a 
developmental exposure to both THC (1.25 and 2.5 mg/L) and CBD (0.07 and 0.1 mg/L) 
(Figure 2.3). THC (0.3, 0.6, 1.25, and 2.5 mg/L), but not CBD exposure, resulted in dazl 
up-regulation (Figure 2.3). In addition, expression of vasa, sox2, sox3, sox9a, bdnf, reln, 
krit1 and cannabinoid expressing gene cnr1 was measured; however, no statistically 
significant differential expression of these genes compared to control was detected.   
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Figure 2.3 THC and CBD gene expression. Differential expression via RT-qPCR of 10 
genes, as compared to reference gene 18s, following a 96 hpf developmental exposure 
to THC, CBD, or DMSO. (↑/-) represents significance (p < 0.05) using ANOVA and 
Tukey’s post-hoc test (n=3). c-fos was differentially expressed in a concentration-
dependent manner in both THC and CBD exposed larvae, while dazl and vasa were only 
differentially expressed by THC. CBD is depicted in only two concentrations due to LC50 
limitations. (Bars with the same letter are not significantly different).      
 
 
 
 
 
Significant (+) differential gene expression after 96 hpf 
exposure to THC or CBD 
Morphogenesis 
 THC/CBD 
c-fos ↑/↑ 
dazl ↑/- 
vasa ↓/- 
sox2 -/- 
sox3 -/- 
sox9a -/- 
krit1 -/- 
Neurogenesis 
bdnf -/- 
reln -/- 
cnr1 -/- 
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2.5 Discussion  
An important result of this study was that similar concentration-dependent 
morphological and locomotor behavioral outcomes following a 96 hpf developmental 
exposure to both CBD and THC were observed. Zebrafish larvae exposed to THC 
displayed very similar adverse outcomes to those previously published (Akhtar et al., 
2013; Thomas, 1975). Toxicities included pericardial/yolk sac edemas and curved axis as 
well as increased locomotor activity at low concentrations of THC; however, implications 
for larval morphology and behavior following CBD exposure was previously unknown. 
CBD exposure at blastula through larval stage increased developmental 
dysmorphologies, especially jaw malformation, at relatively lower LOAELs (0.3 mg/L) than 
THC (5 mg/L). Previously embryo abnormalities such as craniofacial deformities have 
been reported in rodents following gestational exposure to THC (Bloch et al., 1986; 
Harbison et al., 1977; Rosenkrantz, 1999). A/J strain mice exposed to as little as 60 mg/kg 
THC between gestational days 11-14 experienced increased frequency of cleft palate 
(Bloch et al., 1986). These results were also found previously using Swiss-Webster mice 
at much higher doses of THC (300 mg/kg) (Harbison et al., 1977). While numerous 
studies have been conducted on THC developmental abnormalities in rodents; doses, 
routes of administration, and species differences vary. For example, newborn albino rat 
fetuses experienced few abnormalities when parents were exposed prior to mating to low 
concentrations of THC (0.5 – 5 mg/kg) (Wright et al., 1976). Comparative studies have 
been conducted relating development genes during early morphologic stages in the 
mouse (embryonic day 12) and zebrafish (48 hpf) models (Wullimann and Meuller, 2004). 
Additionally, genes such as sox9 have been implicated in craniofacial deformities in both 
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zebrafish (Yan et al., 2005) and mice (Bi et al., 2001), but in our study differential gene 
expression of sox9 was not detected in 96 hpf THC or CBD-treated larvae.   
An additional endpoint that significantly differed between CBD and THC was the 
relative LOAELs for pericardial edema. The THC LOAEL for pericardial edema (0.6 mg/L) 
was roughly ten-times higher than CBD (0.07 mg/L). Enlarged pericardium in larval 
zebrafish can be caused by a number of attributes, including deregulated cardiovascular 
development-oriented genes (krit1), heart failure, or morphologies related to improperly 
placed heart chambers (Chen et al., 1996). In mice, research has shown krit1 mutations 
were present in cerebral cavernous malformations which encompassed vascular lesion 
irregularities, although no connection to cardiovascular morphology was present in 
current literature (Wüstehube et al., 2010). However, we did not observe differentially 
expressed krit1 in 96 hpf whole larval homogenates. This result could be attributed to time 
specific-differential expression that should precede cardiovascular adverse outcomes; 
future work should assess gene expression at multiple developmental time-points.  
Acute effects of THC on the cardiovascular system range widely from increased 
heart rate, blood pressure, and cardiac output to hypotension (Jones, 2002); however, 
whether these endpoints directly affect embryo cardiovascular health is still under 
investigation. Zebrafish pericardial edema morphologies relate to a detrimental toxic 
event during imperative stages of development (somite 21-26; ~19-22 hpf) (Kimmel et al., 
1995; Stainier and Fishman, 1992) and have been studied widely in conjunction with 
known developmental toxicants (Corrales et al., 2014b; King Heiden et al., 2009). More 
studies are needed in order to identify the underlying molecular initiating events for these 
toxicities and whether pericardial edemas caused by cannabinoids are the manifestation 
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of functional cardiovascular abnormalities, signal transduction hindrance, or a 
combination of the two. Per our results, cnr1 mRNA expression was not differentially 
expressed compared to control following THC or CBD exposure; however, additional 
knockout studies are needed to elucidate the extent of cannabinoid receptor involvement 
in initiating morphologic or behavioral phenotypes.  
Molecular reporters for morphogenesis or neurogenesis aberration were a point of 
focus due to the observed organogenesis and behavioral changes in exposed fish. bdnf 
and rln are both imperative for normal brain development and function, for example, bdnf 
differential expression has been observed in patients with Parkinson’s disease, 
Alzheimer’s disease, and dementia while rln assists in neuronal cell migration during brain 
development (Fatemi et al., 2005; Vairo et al., 2015). We did not find any significance in 
bdnf or rln expression following THC or CBD exposure, but will continue to explore the 
possible ramification of cannabinoids on brain development and adult onset of 
neurological disorders in zebrafish. vasa, sox2, and sox3 have been previously studied 
in our laboratory as potential markers of impaired organogenesis or embryogenesis 
(Corrales et al., 2014a; Fang et al., 2013) and are important molecular biomarkers for 
assessing the adverse reproductive effects of cannabis exposure. While we observed no 
differential expression in sox2 and sox3, vasa expression was decreased between the 
0.3 and 1.25 mg/L THC treatments (Figure A2.1), but not statistically different than 
control. vasa is highly expressed in spermatocytes as well as mature oocytes and is highly 
conserved in both invertebrates (e.g. Drosophila) and vertebrates (e.g. Xenopus, chick, 
mouse, and human) during germ cell development (Raz, 2000).  
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 Behavioral abnormalities following acute and chronic exposure to THC are well 
established in both rodents and zebrafish (Akhtar et al., 2013; Champagne et al., 2010; 
Long et al., 2010; Rodríguez et al., 2017). Neonatal THC exposure to C57/BL6 mice 
caused neurotoxicity during early developmental periods leading to schizophrenia-
suggestive behavior in early adult-hood (Rodríguez et al., 2017). CB1-knockout mice 
have increased anxiety-like behavior and more aggressive tendencies than wild-type 
which indicates possible CB1-mediated anxiogenic properties when disrupted (Haller et 
al., 2004). Zebrafish have conserved behavior to rodents following THC exposure 
(Champagne et al., 2010). Following developmental low-concentration THC exposure, 
zebrafish exhibit an increased locomotor activity, but increased concentrations have a 
normalizing effect (Haller et al., 2004). Our results indicate similar neurotoxic effects 
following THC and CBD exposure. Whether or not these results represent anxiogenic-like 
behavior requires further analysis. Stress or anxiogenic-like behavior in larval zebrafish 
is usually represented by a reversal in characteristic light:dark behavior (Ellis et al., 2012). 
We observed hypolocomoter activity in light periods at high concentrations in both THC 
and CBD, but also observed hypolocomoter activity during dark periods which suggests 
a neurotoxic event in neuronal connectivity possibly void of stressful/anxiogenic 
properties (Kim et al., 2013). We did find concentration-dependent increases in c-fos 
expression, which is correlated to increased neural activity and hyperlocomoter behavior 
in zebrafish (Baraban et al., 2005; Morgan et al., 1987). Our initial hypothesis predicted 
CBD to significantly reduce c-fos expression in correlation with hypolocomoter behavior 
due to its anti-convulsant indications (Devinsky et al., 2017); however, both THC and CBD 
upregulated c-fos in a manner that was inconsistent with behavioral outcomes. This 
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outcome may be due to a neurotoxic event affecting molecular signaling and behavioral 
phenotypes.     
Another major goal of this study was to study the basic pharmacokinetic/ 
toxicokinetic characteristics of a cannabis waterborne exposure scenario. While zebrafish 
is an established model for assessing developmental toxicities (Henry et al., 1997) and 
behavioral phenotypes (Nazario et al., 2015a), water-based exposures require water 
concentration and tissue bioconcentration validation. With advancements of CBD 
cultivation and pharmaceutical application, it is imperative to formulate a model that meets 
very high standards for both organismal translatability and high-throughput potentiality. 
Prior studies have subjected adult zebrafish to intraperitoneal (i.p.) injections of CBD, 
which is very time consuming and not applicable for high-throughput applications. In 
addition, the utilization of i.p. injections while assessing locomotor characteristics may not 
be suitable for the sensitive nature of behavioral or developmental screenings. Hence, 
waterborne exposures are less time-consuming and place less stress on the organism 
prior to analysis.  
Previous studies have documented developmental toxicities without providing 
confirmation of cannabinoid concentrations in water or proof of whether or not 
cannabinoids are concentrated in larvae tissue during the exposure period (Akhtar et al., 
2013; Thomas, 1975). We found that CBD, even when used at much lower concentrations 
than THC, tended to bioconcentrate in tissue. While this is counterintuitive due to the 
higher polarity of CBD and lower log P compared to THC, the significantly lower CBD 
LD50 may be attributed to bioconcentration rather than potency.  
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     This study provides a comprehensive morphological and behavioral assessment 
following developmental exposure to THC and CBD. CBD is currently chronically 
accessible to toddler epilepsy patients, hence, proper vetting of developmental and 
reproductive toxicities is needed and can be accomplished in part with the zebrafish 
model. A goal of this project moving forward is to further enhance our knowledge of THC 
and CBD reproductive and multi-generational toxicities. Differentially expressed dazl hints 
toward potential germline deregulation which may hinder reproductive fitness in the 
exposed F0 (Takeda et al., 2009). Because of the relatively conserved neuroanatomy, 
including cannabinoid receptor 1 signaling and behavior between zebrafish and 
mammals, linking molecular to organismal responses will be highly translatable to 
humans (Champagne et al., 2010; Krug and Clark, 2015; Lam et al., 2006; Panula et al., 
2010; Ivan Rodriguez-Martin et al., 2007; Schmidt et al., 2013; Stewart et al., 2014)dt et 
al., 2013; Stewart et al., 2014). This study is foundation for future work, especially 
considering the role of cannabis as a therapeutic in the holistic and pharmaceutical 
industries (Bostwick, 2012).  
 
2.6 Conclusion 
 Our investigation of CBD toxicity is highly relevant to a wide range of medical fields 
of research including toxicology, epilepsy, and cancer (Blair et al., 2015; Cridge & 
Rosengren, 2013). Initially, we hypothesized CBD would be the less toxic cannabis 
constituent compared to THC primarily due to its non-psychotropic properties and weak 
CB1 affinity; however, CBD mirrored THC developmental and behavioral toxicities at 
strikingly lower concentrations. Additionally, CBD bioconcentrated more readily than THC 
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regardless of its lower log P. Because of the developmental toxicities that we detected 
and the overwhelming outcry for novel cannabis-based therapeutics, more research is 
necessary to elucidate the molecular mechanisms and potential downstream EDC targets 
or unrelated EDC off-target effects that may contribute to neurological or developmental 
basis for both developmental and adult onset disease.
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CHAPTER 3 ASSESSING CANNABINOID DEVELOPMENTAL AND REPRODUCTIVE 
TOXICITY IN ZEBRAFISH 
3.1. Abstract 
 The legalization of recreation and medicinal Cannabis sativa is on the rise; 
therefore, exposure rates among the infant, adolescent, and adult populations are 
increasing. While Δ9-tetrahydrocannabinol (THC) has been widely studied in the realm of 
developmental and reproductive toxicology, few studies have investigated potential 
toxicities from a second widely used cannabis constituent, cannabidiol (CBD). CBD is 
currently being popularized for its therapeutic potential for reducing seizure frequencies 
in a catastrophic form of epilepsy, Dravet Syndrome. Dravet syndrome afflicts roughly 
1:16,000 individuals, most of which are diagnosed as infants. Patients often run out of 
treatment options due to Dravet syndrome’s drug-resistant characteristics; therefore, 
many turn to alternative medicines, such as CBD. This study investigated the 
developmental origins of health and disease (DOHaD) by quantitating multigenerational 
gene expression patterns, behavior phenotypes, and reproductive fitness of a subsequent 
F1 generation following an F0 developmental exposure to concentrations of THC or CBD 
below the lowest observed adverse effect level (LOAEL), 0.024, 0.12, 0.6 mg/L (0.08, 0.4, 
2 μM) THC, 0.006, 0.03, 0.15 mg/L (0.02, 0.1, 0.5 μM) CBD, or 0.05% DMSO control in 
zebrafish. During key developmental stages, THC and CBD caused differential 
expression of c-fos, brain-derived neurotrophic factor (bdnf), and deleted-in-azoospermia 
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like (dazl), while only CBD differentially expressed dazl in F1 larvae at 48 and 96 hours 
post fertilization (hpf). In addition, THC reduced larval light:dark behavior in both exposed 
F0 and unexposed F1 larvae. Following THC and CBD exposure, fecundity was reduced 
in a concentration dependent manner. This research outlines a need for future work 
related to CBD toxicities, especially when considering possible ramifications from early-
life exposure.  
 
3.2. Introduction 
 As cannabinoid exposure increases among the United States population, whether 
for recreational or medicinal purposes, it is important to delineate potential hazards 
associated with its use. This is especially crucial for understanding the developmental 
origins of health and disease (DOHaD). Recent literature lacks empirical evidence of 
cannabinoid toxicities during periods at which adverse outcomes may lead to embryo 
toxicities, neurodevelopmental delay, adult disease, or possibly negatively affect 
reproductive outcomes and pose a risk to offspring following parental exposure. Currently, 
29 states have passed medical marijuana legislation within the United Sates; however, a 
number of additional states possess laws specific for CBD drug trials and regulate the 
way in which patients obtain medical cannabis (ProCon.org, 2017). While a previous 
study revealed roughly fifty percent of medical cannabis users are below the age 35, 
strikingly few demographic statistics are available concerning physician-related 
prescriptions to young patients (Nunberg et al., 2011). Moreover, a recent trial 
collaboratively conducted by several top-tier medical institutions and GW 
Pharmaceuticals treated roughly sixty drug-resistant epilepsy patients with a mean age 
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of 9.7 years old and as young as 2.5 years old with CBD (Devinsky et al., 2017). It is of 
great importance to patients, doctors, and the toxicology community to research the 
potential DOHaD following cannabis exposure during early-life stages and through critical 
developmental periods. 
 THC and CBD have been widely used for several millennia to relieve multiple 
indications including insomnia, pain, nausea, satiety, and recently seizure 
frequency/severity (Bostwick, 2012). The latter is cause for concern due to the patient’s 
age, which can be as young as 2 months (Lindsey, 2016). THC has previously been 
implicated in developmental and reproductive toxicities. For example, early research in 
rodents and humans following chronic use, resulted in adverse effects on 
neurodevelopment, cognitive ability, and even adverse reproductive effects such as 
spermatogenic apoptosis (Costa et al., 2015; Nahas et al., 2002; Rodríguez et al., 2017; 
Schönhofen et al., 2015; Tortoriello et al., 2014; Wu et al., 2011). Very few studies have 
focused on CBD’s safety profile; however, our recent work has depicted similar related 
toxicities between THC and CBD in zebrafish (Carty et al., 2017). These related toxicities 
include: morphologically deformed phenotypes, differential regulation of key 
developmental genes, and abnormal behavioral attributes. In view of this, we present 
additional evidence of toxicities resulting from THC and CBD developmental exposure as 
well as multigenerational consequences of an F0 only exposure.   
 Key developmental stages (e.g., toddler through adolescence) are sensitive to 
cannabinoid toxicities due to important periods of neurodevelopment and 
neurotransmitter maturation (Pitsilis et al., 2017). Endogenous cannabinoid ligands, (2-
arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide (AEA), as well as 
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cannabinoid receptors 1 and 2 (CB1 and CB2) are present at varying concentrations and 
expression levels, respectively in zebrafish, chick, rodent, and human development (Fride 
et al., 2009; Krug and Clark, 2015; Psychoyos et al., 2012). In zebrafish, developmental 
CB1 knockdown studies have been conducted to assess its functional characteristics 
(Watson et al., 2008). In these studies, CB1 morpholino mutants exhibited a distinct 
phenotype of disorganized medial longitudinal fasciculi (MLF) and disturbed axonal 
growth (Watson et al., 2008). In chick and rodent studies, cannabinoid receptors, which 
are among a class of G-protein coupled receptors (GPCRs) that transduce their signaling 
via adenylyl cyclase/cAMP and additional downstream mechanisms, are very active 
during early development time periods (Psychoyos et al., 2012). Therefore, exogenous 
ligands such as THC or CBD have the ability to alter these endogenous systems leading 
to adverse developmental outcomes. Adverse outcomes have previously been measured 
in zebrafish following THC exposure, resulting in cognitive impairments such as anxiety, 
learning, and memory (Ruhl et al., 2014; Stewart and Kalueff, 2014); however, no 
previous study has offered comparative analysis of THC verses CBD.    
 Similarly a few studies offer insight into the reproductive and multigenerational 
consequences of THC exposure, but no previous literature has focused on CBD as a 
generational toxicant (Dalterio et al., 1984; Lewis et al., 2012; Thomas, 1975). Previous 
research has shown evidence of multigenerational toxicities in rodents following an 
adolescent exposure to THC (Watson et al., 2015). The primary findings were a reduction 
in pregnancy rates due to parental germline exposure (Szutorisz et al., 2014). The 
reduced pregnancy rates were thought to be correlated with reduced male fertility 
following THC exposure which is well established (Agirregoitia et al., 2010; Costa et al., 
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2015; Lewis et al., 2012; Nahas et al., 2002). The causality for reduced male fertility has 
been less studied; however, CB1 and CB2 are both expressed in human sperm cells and 
are implicated in the regulation of sperm motility (Agirregoitia et al., 2010). These 
multigenerational, loss of reproductive ability effects are most likely attributed to 
epigenetic factors that contribute to altered gene expression phenomena in subsequent 
generations (Watson et al., 2015). 
 Herein, we studied the effects of a F0 generation developmental exposure to THC 
or CBD and how that exposure affected both F0 development and their subsequent 
offspring (F1; second generation) in the context of biomarker gene expression, behavior, 
and reproductive success. This project is novel due to the lack of empirical data 
comparing the toxicities of the two most exploited phytocannabinoids, THC and CBD. In 
addition, evidence of CBD’s therapeutic potential (Devinsky et al., 2017) in children 
diagnosed with drug-resistant forms of epilepsy will inherently increase human exposure 
during critical developmental stages.  
 
3.3 Methods and Materials 
3.3.1 Zebrafish Care and Exposure  
 Tg(fli1:egfp) zebrafish were obtained through the Zebrafish International Resource 
Center (ZFIN, Eugene, Oregon). In brief, adult zebrafish were spawned overnight in 
breeding tanks containing water from an Aquatic Habitats Zebrafish Flow-through System 
(Aquatic Habitats, Apopka, Florida) within the following parameters: pH 7.5-8.0, dissolved 
oxygen 7.2-7.8 mg/L, conductivity 730-770 μS, temperature 27°-29°C. The next morning, 
newly fertilized eggs were randomly sorted into scintillation vials, n = 5 vials per exposure 
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group; 10-30 fish per vial depending on exposure time period (14 hpf n≈30, 24 hpf n≈30, 
48 hpf n≈25, 72 hpf n≈20, 96 hpf n≈15), containing embryo water with a salinity of 60 ppm 
Instant Ocean (Instant Ocean, Cincinnati, Ohio) at pH 7.4-7.7. Beginning at ~2 hpf, 
embryos were exposed to concentrations below the LOAEL, as previously described in 
(Carty et al., 2017), 0.024, 0.12, 0.6 mg/L (0.08, 0.4, 2 μM) THC, 0.006, 0.03, 0.15 mg/L 
(0.02, 0.1, 0.5 μM) CBD, or 0.05% DMSO control water at a 0.6:1 (mLs water:fish) ratio 
in static conditions without a water changes. Culture and exposure protocols were 
previously IACUC approved. The NIDA Drug Supply Program supplied all THC and CBD 
used throughout the developmental exposures.  
 
3.3.2 RT-qPCR 
All concentrations (0.024, 0.12, 0.6 mg/L (0.08, 0.4, 2 μM) THC, and 0.006, 0.03, 
0.15 mg/L (0.02, 0.1, 0.5 μM) CBD, or 0.05% DMSO) were assessed in the F0 generation, 
while only 0.05% DMSO control and high concentrations (0.6 mg/L THC and 0.15 mg/L 
CBD) were assessed in F1s. Zebrafish (F0 and F1) were collected and pooled at 14, 24, 
48, 72, or 96 hpf (n = 5 vials; 15-30 fish per vial) and placed in RNAlater (Invitrogen) and 
then stored at -80°C. Whole embryo/larval tissue was homogenized in TRIzol (Invitrogen 
#A33251) and RNA was extracted using RNeasy mini-kit (Qiagen #74104) and RNase-
Free DNase set (Qiagen #79254) following manufacturer’s recommended protocol. RNA 
was quantified and evaluated for purity on a NanoDrop 2000 followed by reverse 
transcription to 10 ng/μL cDNA (Invitrogen kit #4304134). RT-qPCR was performed using 
an Applied Biosystems 7200 real-time cycler with SYBR Green detection chemistry 
(Applied Biosystems #4309155). Parameters for RT-qPCR were as follows: 95°C for 10 
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min, then 40 cycles of 95°C for 15 sec and 60°C for 1 min, followed by 95°C for 15 sec-
60°C for 1 min-95°C for 15 sec dissociation curve. Primers were optimized previously 
(Fang et al., 2013a) and detailed in Table 3.1. Samples were screened using duplicate 
analytical standards followed by 2-ΔΔCT method evaluation (Livak and Schmittgen, 2001). 
Statistical significance was calculated using one-way analysis of variance (ANOVA) on 
the ΔCT followed by Tukey’s post-hoc test (p ≤ 0.05); however, if significance was not 
obtained using ANOVA, the student’s t-test (p ≤ 0.05) was subsequently used to measure 
significance against control. Error was identified as standard error of the mean (SEM). 
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Table 3.1 RT-qPCR Primers   
Gene Accession Primer sequence r2 Efficiency % 
c-fos BC065466 
F: 5'-CAC CGA TAC ACT GCA AGC TGA A-3' 
R: 5'-CAG GTT GGC GAT GTC GTT CT-3' 
0.997 106.2 
dazl BC076423 
F: 5'-AAT GCC CAG CTT GCC TAA TG-3' 
R: 5'-CAC GCG GCC GAA ACC-3' 
0.974 84.06 
bdnf BC058301 
F: 5’-GAC TCG AAG GAC GTT GAC CTG TA-3’ 
R: 5’-CGG CTC CAA AGG CAC TTG-3’ 
0.977 97.95 
18s FJ915075 
F: 5'-TGG TTA ATT CCG ATA ACG AACGA-3' 
R: 5'-CGC CAC TTG TCC CTC TAA GAA-3' 
 
0.999 75.61 
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3.3.3 Larvae Behavior 
F0 generation zebrafish exposed to CBD, THC, or control (n = 2 vials; ~24 fish per 
vial) for 96 hpf and unexposed F1 generation zebrafish (96 hpf; n = 36-48) were 
transferred to a 96-well plate (one fish per well) followed by a 5-minute acclimation period 
in full light. Larvae exhibiting a lack of touch response or deleterious morphology were 
excluded from the behavioral assessment. Larval zebrafish were assessed in a ZebraBox 
utilizing ZebraLab 3.3 software (ViewPoint, Montreal, Canada). Neurotoxic behavior was 
observed via a 30 min period of light:dark cycling (0-10 min, 100% light; 10-20 min, dark, 
0% light; and 20-30 min, 100% light) (Kirla et al., 2016). Zebrafish locomotor activity with 
a velocity ≥ 5 mm/sec was collected continuously throughout the 30-minute period and 
averaged every two minutes for statistical analysis. (n=2 (F0); n = 36-48 (F1)) using two-
way ANOVA with repeated measure followed by Bonferroni post-tests (p ≤ 0.05). 
 
3.3.4 Reproductive Assessment 
 At 6 months of age, mating pairs (2 male:2 female) of each F0 exposure group 
were placed into static breeding tanks (n = 3-7 breeding tanks per concentration) with 750 
mL system water from our primary zebrafish culture unit (Aquatic Biosystems) and placed 
in a temperature controlled room. Water changes were conducted twice a week and 
during spawning events. Mating pairs were allowed a one-week acclimation period for 
which one spawning event took place. Week two consisted of three consecutive spawning 
days to ensure participation from each male and female. Following each egg collection, 
debris and water were removed and replaced with clean embryo medium (60 ppm Instant 
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Ocean; pH 7.5-7.8). Collected eggs were subsequently counted and screened for 
fertilization, mortality, and hatching every 24 hours until 96 hpf.    
 
3.3.5 GC-MS Water Analysis 
 Exposure concentrations of THC and CBD stock solutions were confirmed in water 
at 0 hpf and 96 hpf, as previously described (Carty et al., 2017; Kudo et al., 1995). In 
brief, we prepared stock exposure water of 1.25 mg/L THC and 0.3 mg/L CBD (0.05% 
DMSO) and diluted to our exposure concentrations. Concentrations in stock water were 
verified by removing 2 mLs and adding THC-d3 (Sigma Aldrich) with a final concentration 
of 10 mg/L and 1 mL of 2 M NaOH followed by a solvent:water extraction into hexane:ethyl 
acetate (H:E) (9:1, v/v). H:E was then evaporated and reconstituted/derivatized in N,O-
Bis(trismethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane (Thermo Scientific) for 
1 hour at 90°C. Samples were then re-suspended isooctance and analyzed on GC-MS 
(Agilent Technologies 6890N; Mass Spectrometer 5973).            
 
3.4 Results 
3.4.1 F0 and F1 Gene Expression 
 Zebrafish were collected at 14, 24, 48, 72, and 96 hpf and analyzed for differential 
gene expression of biomarkers for neurodevelopment (c-fos and brain-neurotrophic 
factor, bdnf) as well as germline fitness (deleted-in-azoospermia-like, dazl). Stock 
exposure water concentrations were verified via GC-MS as follows: 1.25 mg/L THC 
(nominal)  1.13 ± 0.16 mg/L THC and 0.3 mg/L CBD (nominal)  0.08 ± 0.02 mg/L 
CBD. Time point analysis of the F0 generation revealed c-fos to be differentially down-
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regulated, especially later in development (48, 72, and 96 hpf) and at high concentrations 
of THC (0.6 mg/L THC) (Figure 3.1). bdnf also displayed aberrant up-regulated patterns 
of expression at multiple time points (14, 48, and 96 hpf) mostly at 0.6 mg/L THC. While 
dazl also shared differential down-regulation at 96 hpf (0.12 mg/L THC) with c-fos, 14 
(0.024 mg/L THC) and 72 hpf (0.6 mg/L THC) were up-regulated compared to control 
(Figure 3.1).  
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Figure 3.1 THC time point gene expression (F0). Developmental stage specific differential 
expression of c-fos (A-C), bdnf (D-G), and dazl (H-K) following exposure to THC or 
DMSO. Line graphs depict the developmental expression patterns normalized to 14 hpf. 
Bar charts represent time points that were statistically significant throughout development 
normalized to control. Exposure groups were normalized to 18s and analyzed using the 
2-ΔΔCT method (p ≤ 0.05) measured first by ANOVA and Tukey’s post-hoc test (#) or 
student’s t-test (*) (n = 5). c-fos was differentially down-regulated later in development 
(48, 72, and 96 hpf) at 0.6 mg/L THC. bdnf and dazl were primarily up-regulated early 
and late in development including potential concentrations dependence at 48 hpf (bdnf; 
0.6 mg/L THC) and 72 hpf (dazl; 0.6 mg/L THC). Bars represent ± SEM. 
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 CBD developmental F0 exposure lead to fewer significant changes in gene 
expression. c-fos expression at 96 hpf (0.15 mg/L CBD) was significantly higher than 
control; however, at 96 hpf c-fos expression was significantly down-regulated following 
exposure at the lower 0.006 and 0.03 mg/L CBD concentrations (Figure 3.2). bdnf was 
consistently up-regulated during development at 24 and 72 hpf, but only at the highest 
concentrations of CBD (0.15 mg/L; Figure 3.2). While dazl was differentially expressed 
throughout development following THC exposure, CBD was only affective in changing 
expression characteristics early in development (14 hpf) at 0.15 mg/L (Figure 3.2).  
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Figure 3.2 CBD time point gene expression (F0). Developmental stage specific differential 
expression of c-fos (A,B), bdnf (C-E), and dazl (F,G) following exposure to CBD or DMSO. 
Line graphs depict the developmental expression patterns normalized to 14 hpf. Bar 
charts represent time points that were statistically significant throughout development 
normalized to control. Exposure groups were normalized to a reference gene (18s) and 
analyzed using the 2-ΔΔCT method with significance (p ≤ 0.05) measured first by ANOVA 
and Tukey’s post-hoc test (#) or student’s t-test (*) (n = 5). c-fos was significantly up-
regulated at 24 hpf (0.15 mg/L CBD), but down-regulated at 72 hpf (0.006 and 0.03 mg/L 
CBD). At 24 and 72 hpf, bdnf was differentially upregulated at 0.15 mg/L CBD, while dazl 
expression was only significantly affected at 14 hpf (0.15 mg/L CBD). Bars represent ± 
SEM. 
A C F 
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 Fewer adverse changes in gene expression were observed in the F1 generation. 
No significant changes in c-fos or bdnf expression in the F1s were detected. Only dazl 
expression was significantly up-regulated in the F1 generation at 48 and 96 hpf following 
developmental exposure to F0 parents at 0.15 mg/L CBD (Figure 3.3). 
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Figure 3.3 THC and CBD developmental gene expression (F1). F1 developmental stage 
specific differential expression of c-fos, bdnf, and dazl following exposure to THC, CBD, 
or DMSO via RT-qPCR. Exposure groups were normalized to a reference gene (18s) and 
analyzed using the 2-ΔΔCT method with significance (p ≤ 0.05) measured by student’s t-
test (p ≤ 0.05) (n = 5). For reference, line graphs depict the developmental expression 
patterns normalized to 14 hpf, while the bar charts represent time points that were 
statistically significant. THC (0.6 mg/L) did not provide any multigenerational differential 
expression (F1) following a development exposure to F0 parents. However, offspring of 
parents developmentally exposed to 0.15 mg/L CBD differentially expressed dazl at 48 
and 96 hpf. Bars represent ± SEM.   
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3.4.2 F0 and F1 Locomotor activity  
 Locomotor activity was conducted at 96 hpf and limited to larvae with normal 
morphologic features. In F0 larvae, statistically significant hypolocomotor activity was only 
observed in larvae exposed to the lowest concentration of THC (0.6 mg/L), (Figure 3.4). 
No additional statistically significant locomotor activity was detected in F0s compared to 
control. F1 larvae presented more significant behavioral phenotypes. F1 larvae from 
parents exposed to the lowest concentration of THC (0.024 mg/L) displayed a reduction 
in locomotor activity at 12-20 minutes of darkness, mirroring their parents’ hypolocomoter 
phenotype (Figure 3.4). However, we did not observe a concentration dependence in 
locomotor activity in THC F1s exposed offspring. Offspring of parents exposed to 0.12 
mg/L THC exhibited increased locomotor activity, while the highest concentration (0.6 
mg/L THC) proved to be unchanged compared to control (Figure 3.4). F1 larvae from 0.03 
mg/L CBD exposed parents displayed a reduction in locomotor activity while their parents, 
at the larval stage, were unaffected.   
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Figure 3.4 THC and CBD larval zebrafish behavior in F0 (A,B) and F1(C,D). F0 and F1 
larval zebrafish behavior were assessed at 96 hpf for locomotor activity in a ViewPoint 
ZebraBox for a total of 30 minutes (0 – 10 min, light: 10 – 20 min, dark (grey box): 20 – 
30 min, light) as described in (Carty et al., 2017). Locomotor durations greater than a 
velocity of 5 mm/sec were averaged per 2 minute time frame and analyzed for statistical 
significance using two-way ANOVA with repeated measures followed by Bonferroni post-
hoc test (n = 2 (F0), n = 36-48 (F1), p ≤ 0.05). Concentrations along with (n) are provided 
in the graphs above. Bars represent ± SEM.   
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3.4.3 F0 Reproductive Success and F1 Survival 
 Following three consecutive days of egg collection from 6-month old F0 
developmentally exposed to sub-LOAEL concentrations of either THC or CBD, total 
offspring, survival, fertilization, and hatching rate were examined (Table 3.2). When 
comparing total eggs, we observed a trend toward reduced fecundity in F0s exposed to 
CBD (0.024 mg/L) and THC (0.024 and 0.12 mg/L) (Table 3.2). It should be noted, two 
control tanks did not perform well due to uncharacteristically low fecundity and abnormally 
high mortality rates; therefore, we omitted these tanks from our statistical analysis. 
Survival and fertilization percentages were not affected in the F1 generation. While we 
have previously observed delayed hatching rates in zebrafish larvae exposed to high 
concentrations of CBD (Carty et al., 2017), at sub-LOAEL concentrations we did not find 
any significant change at 48 or 72 hpf (Table 3.2).   
 
 
 
  
 
8
3
 
 
 
 
  
Table 3.2 F0 fecundity and F1 survival  
Compound 
Nominal Water  
Concentration mg/L 
at 0 hpf (tanks) 
Total Eggs/ 
Average per 
tank 
% Survival % Fertilized 
% Hatched 
48 hpf 
% Hatched 
72 hpf 
Control 0.05% DMSO (7) 1050/150 74.0 ± 7.2 98.5 ± 1.0 11.7 ± 6.2 79.3 ± 11.4 
THC 0.024 (3) 192/64a 89.8 ± 4.8 100.0 ± 0.0 16.8 ± 14.2 95.7 ± 2.3 
 0.12 (3) 183/61a 60.4 ± 31.8 99.2 ± 0.8 25.0 ± 14.1 99.2 ± 0.8 
 0.6 (6) 554/111 97.7 ± 1.3 93.5 ± 5.4 16.6 ± 4.7 94.7 ± 2.6 
CBD 0.006 (6) 1152/192 86.6 ± 5.2 95. 1 ± 2.2 23.7 ± 4.2 83.2 ± 8.2 
 0.03 (6) 683/114 87.3 ± 5.2 98.6 ± 0.4 14.4 ± 2.7 96.0 ± 1.5 
 0.15 (4) 253/63a 60.4 ± 9.2 90.7 ± 8.1 11.2 ± 4.0 86.6 ± 12.2 
± SEM 
a One-way ANOVA; Tukey’s (p < 0.05) 
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3.5 Discussion 
 Cannabinoid exposure is increasing among young children and adolescents due 
to therapeutic advancements for the treatment of drug-resistant epilepsy (Devinsky et al., 
2017); therefore, the goal of this study was to assess the multigenerational risk of early 
life exposure to either THC or CBD. An important finding from this research is the potential 
carry-over of differentially expressed genes that may lead to reduced reproductive 
success.  
 Belonging to the Daz gene family, dazl is involved in male infertility and primordial 
germ cell (PGC) formation. PGCs emerge early in development from maternally inherited 
germplasm and are essential for spermatocyte and oocyte success leading to 
multigenerational lineage (Seervai and Wessel, 2013). Many factors, including dazl, are 
involved in germplasm organization which is imperative for the formation of viable PGC 
clusters and PGC specificity (Campbell et al., 2015; Hashimoto et al., 2004). Homologues 
of dazl, which derives its name from being deleted-in-azoospermia phenotypes, have 
been reported across many invertebrate and vertebrate species including Drosophila, C. 
elegans, Xenopus, medaka, mice, humans, and zebrafish (Anderson et al., 2007; Li et 
al., 2016; Seboun et al., 1997; Takeda et al., 2009). Maternally inherited dazl has been 
observed in newly fertilized zebrafish embryos as early as the 4-cell stage (1 hpf) through 
the sphere stage (4 hpf) and located distally in cleavage planes (Hashimoto et al., 2004); 
therefore, evidence suggests dazl is involved in both zebrafish embryogenesis and PGC 
development (Hashimoto et al., 2004). In this study, we use dazl expression as a 
correlative marker for germline fitness leading to compromised reproductive success in 
subsequent generations (Li et al., 2016).  
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 Previously, we have studied dazl and how its expression is sensitive to xenobiotic 
exposure via hypermethylation patterns. Specifically, parental exposure to 
benzo[a]pyrene (BaP) caused hypermethylation of the dazl promoter and decreased dazl 
gene expression leading to a reduction in germline formation and F1 offspring (Corrales 
et al., 2014). Herein, we assessed dazl expression as early as 14 hpf due to PGCs 
completing their migration to gonadal tissue at roughly the 15-somite stage (16.5 hpf) 
(Dosch, 2015). Following CBD exposure in F0 larvae, dazl was differentially expressed in 
both F0 and F1 generations. In the F0s, THC and CBD differentially expressed dazl during 
the segmentation stage (14 hpf) of developmental which can effect germline development 
and PGC maturation. We also observed a significant decrease in offspring coupled in 
zebrafish with down-regulated dazl. In the F1 generation, dazl was differentially 
expressed, which may be less impactful on subsequent generations; however, future 
generations will also be assessed to determine potential rescued reproductive 
phenotypes.  
 The potential adverse effects of dazl expression are not limited to zebrafish. In 
mice, dazl mutations lead to a loss of oocyte formation in females and a complete loss of 
germ cells regardless of sex (Ruggiu et al., 1997). DazlaTm1hgu/+ and DazlaTm1hgu/ 
DazlaTm1hgu male mice produce very little or no sperm, respectively, while in homozygous 
females lack ova and follicles. In addition, ovary tissue was markedly decreased 
compared to wild-type and histology of testicular tissue showed a significant interruption 
in germ cell formation during spermatogenesis (Ruggiu et al., 1997). In humans, dazl 
expression in ovary can be measured as early as gestational day sixty one and increases 
exponentially through gestational week nineteen (Anderson et al., 2007). While 
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expression of dazl in human fetal testis is lower compared to ovary tissue, dazl is 
expressed consistently from first and second trimesters. Also, germ cell size in fetal tissue 
directly correlates with cells expressing the DAZL protein rather than adjacent cells only 
expressing another germ cell protein, VASA (Anderson et al., 2007). dazl has proven to 
be a very important developmental and reproductive biomarker across many species and 
the effect of cannabinoids on dazl expression has not previously been shown.  
 In order to assess neurodevelopment and potential neuronal activity in exposed 
larvae, we measured c-fos and bdnf at multiple developmental time points. Our 
observations concluded that unexposed F1 generation larvae expressed c-fos and bdnf 
similar to control and were not sensitive to parental exposure to THC or CBD. However, 
F0 larvae exposed to THC or CBD were sensitive to cannabinoid exposure resulting in 
differentially expressed c-fos and bdnf throughout development. The rationale for using 
c-fos in this study to represent neuronal activity is well established (Baraban et al., 2005; 
Buenafe et al., 2013; Ellis et al., 2012; Kalueff et al., 2014; Rahn et al., 2015). c-fos 
expression has also been directly correlated with seizure generation as well as anxiety 
behavior (Baraban et al., 2005; Jesuthasan, 2012).  
 Medicinal cannabis, as it relates to c-fos expression, may be important in future 
studies to determine the therapeutic potential of not only reducing behavioral phenotypes 
of epilepsy, but also molecular mechanisms leading to seizure propagation. For example, 
CBD can reduce protein levels of c-fos and reduce catalepsy phenotypes due to 
haloperidol exposure in male Swiss mice (Sonego et al., 2016). Interestingly, the 
attenuation of catalepsy behavior is likely 5-HT1A mediated as opposed to typical GPCR 
signaling (Sonego et al., 2016). While CBD signal transduction pathways are still under 
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investigation, c-fos is a likely candidate for dysregulation following CBD exposure both 
seen in our present study and in current literature.  
 bdnf is ubiquitously expressed throughout human, mammalian, and zebrafish 
brains and is critical for CNS function and development (Cacialli et al., 2016; Cunha et 
al., 2009; Murer et al., 1999). In mice, bdnf mRNA transcripts have been observed in 
newborns through adulthood in the brainstem, cerebral cortex, hypothalamus, and 
hippocampus (Hofer et al., 1990). Utilizing immunoreactivity techniques, previous studies 
found bdnf expression in normal human brain tissue spread throughout the CNS in cell 
bodies of neurons, synaptic boutons, axons, and dendrites (Murer et al., 1999). 
Interestingly, human brains of Alzheimer’s disease lack bdnf which directly implicates its 
expression with neurodegeneration and cognitive impairment (Peng et al., 2005). While 
studies have shown that either a decrease or an increase in bdnf poses a threat for 
potential onset of adult disease, a consensus has been met that bdnf is involved in the 
process of neuronal impairment, survival, and function (Angelucci et al., 2010).  
 The primary pathway for BDNF protein signal transduction is through the TrkB 
pathway, and they together affect numerous functions including neuronal plasticity, 
neuronal survival, learning and memory and as previously mentioned, neurodegenerative 
diseases (Bekinschtein et al., 2008; Cacialli et al., 2016; Cunha et al., 2009). In zebrafish, 
maternally inherited bdnf is observed through 24 hpf followed by steady endogenous 
increase in expression past eight days post fertilization (dpf) (De Felice et al., 2014). We 
observed significant up-regulation of bdnf at very early stages of development (14 hpf) 
through stages post-embryogenesis (96 hpf). In transgenic mice, BDNF overexpression 
has been directly correlated with learning and memory impairment (Cunha et al., 2009). 
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Therefore, it is imperative to uncover the possible ramifications of increased bdnf 
expression in developing zebrafish. While the F1 generation of THC and CBD exposed 
zebrafish did not carry-over a differential expression of bdnf, we have yet to analyze the 
adverse effects of larval bdnf expression on adult zebrafish behavior and cognitive 
abilities.  
 Several recent studies outline the therapeutic and potential adverse effects of 
cannabinoids and their influence on bdnf expression (Butovsky et al., 2005; Campos et 
al., 2015; D’Souza et al., 2009; ElBatsh et al., 2012; Fishbein et al., 2012; Mori et al., 
2017; Winsauer et al., 2015). Consistent with our results, moderate (1.5 mg/kg) and low 
(0.002 mg/kg) doses of THC upregulate BDNF expression in various regions of brain 
tissue in mice (Butovsky et al., 2005; Fishbein et al., 2012). Additionally, low-doses of 
THC can cause minor cognitive impairment, but may potentially be protecting against 
severe damage following convulsant exposure such as PTZ (Fishbein et al., 2012). 
Regulation of cannabinoid signaling via CB1 can also be modulated by BDNF, which 
presents broad implications in cannabinoid mediated toxicities relevant to the EDC (De 
Chiara et al., 2010). CBD has also been investigated for potential protective roles in 
cognitive impairment as it relates to BDNF expression (Campos et al., 2015; Mori et al., 
2017). Specifically, cerebral malaria (CM) mice, co-treated with artesunate and CBD 
experience reduced cognitive deficits versus to artesunate treatment alone (Campos et 
al., 2015). More research is needed to identify the exact mechanisms for the detrimental 
versus beneficial roles of THC and CBD.  
 Another major goal of this study was to uncover potential behavior abnormalities 
in larval zebrafish following a sub-LOAEL exposure to THC or CBD. We also wanted to 
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study the likelihood of F0 behavioral phenotypes carrying-over to the F1 larvae that lacked 
direct cannabinoid exposure. In our previous study, THC and CBD caused a 
concentration-depend reduction in locomotor behavior in 96 hpf zebrafish leading to 
significant hypolocomotor activity at 1.25 mg/L THC and 0.3 mg/L CBD (Carty et al., 
2017). In the current study, we also observed significant hypolocomoter activity, but at 
very low concentrations of THC in the F0 generation. Additionally, the F1 generation also 
possessed a hypolocomotor phenotype at reduced concentrations of both THC and CBD 
compared to control. We are uncertain why THC and CBD affect locomotor activity in a 
concentration dependent manner; however, previous work in this area has also reported 
an inverted U-shaped locomotor concentration-response to CBD with regard to 
anxiogenic behavior (Nazario et al., 2015a). Another interesting aspect of these data is in 
c-fos expression. As mentioned previously, c-fos expression has been directly correlated 
with seizure-like attributes and our observations follow this trend. c-fos expression in F0s 
was down-regulated at 96 hpf in 0.6 mg/L THC and 0.006, 0.03 mg/L CBD exposed 
larvae; contrastingly, we did not observe adverse phenotypical behavior in these groups. 
F1 generation larvae, at 96 hpf, somewhat mirrored the F0 hypolocomotor phenotypes, 
but more research is needed to properly establish an explanation for these results.  
  Significant observations were made in both molecular markers and reproductive 
success; however, there are some limitations to consider. While we verified our stock 
exposure concentrations at time 0 hr, some of our measured concentrations at 96 hr were 
below the limits of detection for our GC-MS. It was the goal of this study to expose 
zebrafish at concentrations in which minimal dysmorphologies were present; however, it 
is plausible that higher concentrations could potentially result in increased gene 
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expression, reproduction, and behavioral abnormalities. Future studies are necessary to 
further elucidate the impact of increased cannabinoid concentrations on development of 
F0s and subsequent generations.  
  
3.6 Conclusion 
 Herein, we established for the first time, a multigenerational zebrafish model for 
investigating the potential developmental toxicities following THC or CBD exposure. This 
study is relevant due to the increased therapeutic treatment opportunities of cannabinoids 
in young children for the treatment of devastating forms of epilepsy. Due to previously 
conducted research, our initial hypothesis was that THC would be more multigenerational 
and neurologically toxic compared to CBD. While we did observe reproductive 
deficiencies and molecular clues for neurotoxicity following THC exposure, we also 
observed similar results following CBD exposure. These results indicate a clear need for 
additional cannabis-based studies in order to better understand the mechanistic 
properties of cannabinoids and to realize the potential risks of its therapeutic application. 
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CHAPTER 4 CONCLUSION AND FUTURE DIRECTIONS
 Cannabis sativa has been used for several millennia as a homeopathic remedy of 
common ailments such as pain, sleep, and hunger. Recently, the chemical elucidation of 
cannabis extracts has revealed THC and CBD as the primary active compounds 
containing pharmaceutical promise. As mentioned in historical data and through our own 
observations, THC is a well-documented developmental, reproductive, and behavioral 
toxicant. We used THC as a positive control to measure against the potential toxicities of 
CBD, for which less is known. Following a rigorous exposure paradigm to elucidate 
phenotypical cannabinoid toxicities, we provide evidence that CBD poses similar risks to 
development, reproduction, and behavior as THC. To our knowledge, this is the first study 
to systematically compare the harmful effects of the two most prevalent 
phytocannabinoids. In addition, this is the first time our lab has scrutinized behavioral 
phenotypes in larval and eventually adult zebrafish as a toxicological endpoint.  
 In our initial cannabinoid exposure, we exposed Tg(fli1:egfp) zebrafish (~6 hpf) to 
0.3, 0.6, 1.25, 2.5, and 5 mg/L (1, 2, 4, 8, 18 μM) THC, 0.07, 0.1, 0.3, 0.6, and 1.25 mg/L 
(0.25, 0.5, 1, 2, 4 μM) CBD, or 0.05% DMSO in glass scintillation vials (n = 3 vials per 
concentration; 10 fish per vial). Concentrations were selected to be slightly above the 
previously published THC LC50 (3.37 mg/L (Noyes et al., 2015)) and extend into relevant 
therapeutic concentrations. Zebrafish were then assessed for adverse morphological 
phenotypes and behavioral abnormalities, followed by RT-qPCR analysis of important 
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developmental biomarkers (Figure 2.1-2.2). While, the previously published THC LC50 
was confirmed by our exposure, we did not expect the CBD LC50 to be upwards of seven 
times lower. This insinuates that CBD is far more potent than its cannabis counterpart, 
THC. In order to test potency, we analytically derived bioconcentration factors from both 
THC and CBD and found CBD to be more bioconcentrated than THC. More research is 
required to pinpoint additional analytical endpoints such as steady state, entry points, 
metabolism, and compound degradation; however, our observations hint that CBD is 
simply more bioavailable not necessarily more potent than THC.  
 In our initial trials, THC and CBD exposures also revealed similar adverse 
morphological phenotypes, consistent with a toxic initiating event early in zebrafish 
development. Two morphological observations were made characterizing differences 
between THC and CBD exposure:  
 CBD caused dysmorphology at concentrations lower than that of THC, and 
 at concentrations ≥ 0.6 mg/L CBD, we observed a non-hatched phenotype. 
  While the analytical chemistry approach answered questions concerning the 
higher potency of CBD, we did not investigate the non-hatched or delayed-hatched 
phenotypes. Future analysis of CBD’s potential effect on zebrafish hatching enzymes 
(Sano et al., 2008) or the likelihood of CBD concentrating on the surface of the chorion 
increasing rigidity resulting in reduced shedding could be further investigated.  
 Molecular endpoints would inform mechanism of action following a developmental 
exposure to THC and CBD. From our gene-list that included markers for both neuronal 
development and morphogenesis, only c-fos was differentially regulated in a 
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concentration-dependent manner. A gene with potentially the most significant 
multigenerational implications, dazl, was also deregulated following THC (F0) and CBD 
(F1) exposure. Gaps exist in our assessment of differentially expressed genes caused by 
THC or CBD exposure; therefore, we are currently embarking on transcriptomic analysis 
via RNA-seq of developmentally exposed zebrafish.  
 Following our initial exposure, we set out to study two additional aspects of 
zebrafish development following cannabinoid exposure: 
1. Are genes that are critical for neuronal growth and reproductive fitness differentially 
regulated at critical stages of development, and  
2.  is there carry-over of differentially expressed genes to subsequent generations. 
 In order to answer these questions, we reduced the exposure concentrations which 
allowed survival through adulthood. Zebrafish embryos were collected and exposed in a 
similar fashion to the initial exposure at concentrations: 0.024, 0.12, and 0.6 mg/L (0.08, 
0.4, 2 μM) THC, 0.006, 0.03, and 0.15 mg/L (0.02, 0.1, 0.5 μM) CBD, or 0.05% DMSO (n 
= 5; 10 – 30 fish per vial depending on time point). In addition to lower exposure 
concentrations, we also assessed gene expression at several time points (14, 24, 48, 72, 
and 96 hpf) throughout development of both F0 and F1 generations. THC was more 
effective than CBD at deregulating c-fos, bdnf, and dazl throughout development, but 
CBD, not THC, caused differential expression (dazl) in the F1 generation. CBD also 
decreased offspring in exposed F0s. Correlating dazl expression across generations to 
fecundity, especially in F2 generation, is a future aim of this project.  
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 One major accomplishment of this project was establishing, for the first time in our 
lab, a behavioral endpoint for neurotoxicity. Through transitional light:dark locomotor 
activity, we were able to characterize a toxicity phenotype of THC and CBD. Low and high 
concentrations resulted in reduced locomotor activity, while mid-ranged concentrations 
culminated in increased locomotor activity. Unfortunately, a technical mistake was made 
in the experimental design leading to reduced samples sizes while conducting statistical 
significance. Even though individual larvae were placed in each well of a 96-well plate 
and scrutinized separately, the original exposure vessels contained pooled larvae; 
therefore, we lost statistical power due to averaging locomotor data per exposure vessels. 
Future behavioral exposures should be exclusively conducted in well-plates with 
individual larvae in each well.    
 A future goal is to assess F0 and F1 adult behavior. After 96 hr exposures to 
cannabinoids, a subset of larvae (minimally 100 per treatment per concentration) will be 
raised in clean conditions to adults (12-16 months). As adults, n = 16 will be subjected to 
a T-maze spatial learning test and a 6 min open-field test as described in (Saili et al., 
2012), respectively using Noldus equipment and Ethovision XT tracking software. In the 
T-maze one arm will have artificial grass and marbles representing a favorable habitat. 
Novelty and social isolation stress will be reduced over 3 days of habituation (1 hr; 2x/day) 
followed by 2 training trials (1/ day). On days 5 and 6, in two trials (3 hrs apart), we will 
track how long it takes each fish to select and remain in the “favored” reservoir for 20 sec 
(n = 16 with 4 trials per fish). If there is a persistent adverse effect on learning, the time 
to reach the favored reservoir will not be reduced relative to the earlier test and will be 
longer than in controls. In the open field test, fish will be placed in the center of a 21 cm 
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diameter cylinder filled with water to 12 cm. Their movement will be tracked for 6 min to 
calculate time spent per zone, distance travelled and number of visits to central and 
peripheral zones to characterize thigmotaxis (peripheral swimming). Increased anxiety 
will be consistent with erratic movement and thigmotaxis. 
 Additional future goals include molecular techniques such as whole-mount in situ 
hybridization to identify altered gene expression of cannabinoid receptors and 
developmental genes in specific tissue, test sex-specific effects on reproduction, and to 
potentially even measure gamete viability and quantity. Through these future aims, we 
hope to better understand the mechanisms of cannabinoid toxicity and build upon the 
challenges of generating an adverse outcome pathway for THC and CBD-mediated 
developmental effects.  
 Some pitfalls that may have limited the results of this project include the medium 
in which we exposed developing zebrafish, the zebrafish itself, and larval behavior. Both 
THC and CBD are highly lipophilic compounds only soluble at very low concentrations in 
water. We anticipated this shortcoming; therefore, we verified all exposure concentrations 
in exposure water and exposed zebrafish tissue. We also realize the zebrafish has its 
own set of limitations. While the endocannabinoid system is well characterized in 
mammals, less research has been conducted to elucidate endocannabinoid function and 
signaling in zebrafish. However, endocannabinoid receptor expression patterns in 
zebrafish are known at a high enough degree to allow for confidence in this area. Lastly, 
zebrafish larval behavior relating to a toxic event during development is still under scrutiny 
and more work is necessary to define behavioral phenotypes during early developmental 
periods.   
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 The original null hypothesis (H0) that THC and CBD would not alter gene 
expression that support phenotypic/behavioral defects or compromise adult reproduction 
were both rejected. These compounds pose a significant risk to zebrafish development 
and behavior even at concentrations significantly below the LC50. While most patients 
with drug-resistant forms of epilepsy resulting in debilitating seizures are choosing 
cannabinoids in desperation, more research is necessary in mechanisms underlying 
developmental toxicity to better understand the potential concerns related to their use.  
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APPENDIX I Analytical characterization of phytocannabinoids
 Extracting THC and CBD from an aqueous environment or larval tissue proved to 
be challenging and required extensive optimization. Our method was adopted from (Kudo 
et al., 1995) with minor amendments as needed. While final methods are described in 
Chapter 2; briefly, THC, CBD, and surrogate standard THC-d3 were extracted from water 
or tissue using liquid:liquid extraction techniques using hexane:ethyl acetate (9:1, v/v). 
Following the phase transition of THC, CBD, or THC-d3, the cannabinoids were 
derivatized using N,O-Bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosaline 
(Thermo Scientific), reconstituted in isooctane, and quantified on a GC-MS (Agilent 
Technologies 6890N; Mass Spectrometer 5973) with DB-5MS column (Agilent 
Technologies). GC-MS parameters were as follows: starting temperature of 100°C (3 
min), ramp to 180°C (30°/min), ramp to 300° (10°C/min), 300° (3 min). Helium was the 
gas phase at 25 kPa with a flow of 0.5 mL/min (Kudo et al., 1995). Calibration curves 
were prepared similar to samples by spiking known concentrations in hexane:ethyl 
acetate (9:1) followed by derivatization and resuspension in isooctane. Standards 
contained THC, CBD, and THC-d3 at 0.016, 0.08, 0.4, 2, and 10 mg/L. Figure A1.1 depicts 
the calibration curve, slope-intercepts and R2 values for all three cannabinoids. GC-MS 
chromatograms and structures for THC (Figure A1.2), CBD (Figure A1.3), and THC-d3 
(Figure A1.4) as well as a chromatogram of a single sample containing all three 
compounds (Figure A1.5) are also shown.  
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Figure A1.1 THC, CBD, and THC-d3 Calibration Curves. THC, CBD, and THC-d3 were 
spiked into 9:1 (v/v) hexane:ethyl acetate followed by derivatization. Representative R2 
values and slope-intercept equations are depicted above. Y-axis (GC-MS abundance), 
X-axis (mg/L).  
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Figure A1.2 Representative chromatogram generated by derivatized THC (10 mg/L). 
Retention time, 8.167 min; quantitative ion, 386 m/z; qualitative ion, 371 m/z.  
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Figure A1.3 Representative chromatogram generated by derivatized CBD (10 mg/L). 
Retention time, 6.936 min; quantitative ion, 390 m/z; qualitative ion, 458 m/z.
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Figure A1.4 Representative chromatogram generated by derivatized THC-d3 (10 mg/L; 
I.S. concentration). Retention time, 8.142 min; quantitative ion, 389 m/z; qualitative ion, 
374 m/z. 
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Figure A1.5 Chromatogram of derivatized CBD, THC, and THC-d3 (all at 10 mg/L) in same 
sample.  
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 In order to verify cannabinoid concentrations in water and tissue, as well as to 
assess the relative loss of THC and CBD throughout our exposure periods (0, 4, 14, 24, 
48, 72, 96 hpf), THC (Figure A1.6) and CBD (Figure A1.7) were analyzed in exposure 
water, with and without zebrafish, as well as the amount bioconcentrated in larval tissue. 
Concentrations of THC and CBD decreased throughout the 96-hour exposure period in 
water in vials both with and without fish. After 96 hours, exposure water including 
zebrafish contained less THC and CBD than water samples where zebrafish were not 
added. We believe this result is due to tissue uptake; however, more analysis is needed 
in order to track the exact fate of cannabinoids in an aqueous medium within glass vials 
containing organic matter.  
 We also assessed the concentrations of bioconcentrated THC and CBD in larval 
tissue at 0, 4, 24, 48, 72, and 96 hpf. Concentrations of THC and CBD increased over 
time and peaked at 96 hpf (62.9 μg/g THC and 238.4 μg/g CBD) (Figure A1.6 and A1.7). 
However, it should be noted that only the highest concentrations (2.5 mg/L THC and 0.3, 
0.6, 1.2 mg/L CBD) were within detection limits. In chapter 3, the increased 
bioconcentration of CBD or THC which seems to be independent of THC and CBD’s 
individual lipophilicity is discussed.     
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Figure A1.6 Time point exposure analysis of THC. THC concentrations decreased over 
time similarly in water with and without zebrafish present. THC is most likely 
bioconcentrating in tissue which is decreasing water availability and in turn decreasing 
detectable H2O concentrations while increasing tissue concentrations. THC (2.5 mg/L) 
was highly bioconcentrated, while lower concentrations were undetectable.  
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Figure A1.7 Time point exposure analysis of CBD. CBD behaved similarly to THC in 
dosed water with and without zebrafish present. CBD bioconcentrated in fish exposed to 
0.3, 0.6, and 1.2 mg/L CBD, but was undetectable at lower H2O concentrations (0.075 
and 0.15 mg/L). 
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APPENDIX II F0 biomarker gene expression  
 During the initial F0 THC and CBD exposures, gene expression of multiple genes 
(vasa, sox9a, sox3, sox2, rln, krit1, cnr1, bdnf) was measured and found to be non-
significantly changed relative to controls. These non-significant results were excluded 
from our publication in Toxicological Sciences and Chapter 2. For future reference, this 
data is included in Figure A2.1.    
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Figure A2.1 Insignificant Chapter 2 THC and CBD gene expression at 96 hpf (F0). RT-
qPCR results for which no significance was found compared to control (0.05% DMSO) 
following a 96 hpf exposure to THC or CBD. Significant differential expression was 
observed in vasa expression between 0.3 mg/L THC and 1.25 mg/L THC; however, no 
statistical difference was observed compared to control. All data points were analyzed via 
one-way ANOVA followed by Tukey’s post-hoc test. 
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APPENDIX III F0 and F1 multigenerational gene expression  
 Time point analysis of c-fos, bdnf, and dazl expression in the F0 and F1 generation 
generated comprehensive amounts of PCR data. To make Chapter 3 and subsequent 
publications more concise, compiled data and PCR results lacking statistical significance 
were omitted. For full disclosure and future reference, all data is included below in Figures 
A3.1-A3.4.   
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Figure A3.1 Compiled developmental stage specific gene expression from Chapter 2 (F0). 
Time and concentration dependent trends of c-fos, bdnf, and dazl expression following 
F0 embryonic exposure of THC or CBD measure at 14, 24, 48, 72, and 96 hpf. Results 
are normalized to their individual time point controls (n=5, p<0.05) 
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Figure A3.2 Non-significant F1 developmental stage specific gene expression from 
Chapter 3 (c-fos). c-fos was upregulated during early development (14, 24, and 48 hpf) 
in unexposed offspring from parents exposed to CBD, but this data was not statistically 
significant using one-way ANOVA and Tukey’s post-test or student’s t-test compared to 
control. Normalized to control at each developmental time point. (n=5, p<0.05)  
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Figure A3.3 Non-significant F1 developmental stage specific gene expression from 
Chapter 3 (bdnf). bdnf expression was not differentially regulated during zebrafish 
development in offspring from parents exposed to either THC or CBD using one-way 
ANOVA and Tukey’s post-test or student’s t-test. (n=5, p<0.05) 
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Figure A3.4 Non-signficant developmental stage specific gene expression from Chapter 
3 (dazl). While dazl expression was statistically different at 48 and 96 hpf, dazl expression 
was not differentially regulated at 14, 24, or 72 hpf in offspring from parents exposed to 
either THC or CBD using one-way ANOVA and Tukey’s post-test or student’s t-test. (n=5, 
p<0.05) 
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